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INTRODUCTION 
canplement is one of the major innate oonspecific mechanisms for 
host defense in serum. More than a dozen proteins have been isolated 
from serum which have a function in either the activation or regula­
tion of complement action. Complement is similar to the coagulation 
sequence in that it comprises a number of precursor proenzymes in 
plasma that are sequentially cleaved to generate biologically and en­
zymatically active proteins. A variety of agents may activate comple-
ment by either of tv.o pathways, the "classical" or "alternative". The 
classical pathway is activated primarily by antigen-antibody complexes 
of at least two IgG and antigen or one IgM and antigen (Figure 1). 
The antigen-antibody complex interacts with the first component of 
canplement, Cl. Cl is composed of three subunits, Clq, Clr and Cls 
held together in a calcium-dependent complex. The interaction of Clq 
with the Fe fragment of the immunoglobulin molecule results in conver­
sion of Clr and Cls to active proteolytic enzymes. Cl cleaves the 
fourth and second components of ccmplement, C4 and C2, and in the pre­
sence of Mg++ they form the classical pathway =nvertase, C42, whose 
next subs trate is C3. The alternative pathway is a more primitive 
form of recognition of "foreign" materials since it does rot require 
the presence of specific antibody. It is activated by such things as 
gram negative bacterial endotoxin, inulin, or zymosan (Figure 2). C3 
or C3b, which is the initial cleavage product of C3; interacts with 
factor B in the presence of Mg++ and the enzyme factor D to form the 
Figure 1. Activation and regulation of the classical pathway of 
CXII!Plement. E are sheep erythrocytes. A is antibody to sheep 
erythrocytes. 
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Figure 2. Activation and regulation of the alternative pathway of 
carrplement. 
4 
IJ) 
ACTIVATION 
C3 
I ... , � ""C3bBb 
C3�3/
3a 
C3b 
REGULATION 
Factor! �
. 
C3b �3bi 
Factor H 
C3bBb 
Fact
S::: 
" "'" 
-� Bb 
6 
alternative pathway oonvertase, C3bBb, whose substrate is additional 
C3, thus forming a :pOsitive amplification loop. The association of 
C3b with either the classical or alternative pathway oonvertases al­
lows them to use CS as a substrate. Cleavage of CS may lead to assem­
bly of a complex of the terminal complement components, CSb, C6, C7, 
C8 and C9. Attachment of CSb-C9 to the membrane of the target leads 
to lysis by channel formation and subsequent ion loss by the target. 
There are three �rtant methods of regulation of. complement 
activation in plasma. First, there are circulating inhibitors of in­
dividual complement components, such as Cl Inhibitor, which irrever­
sibly inactivates Cl by binding as a false substrate (1, 2), and C3b 
Inactivator, or factor I, which cleaves C3b and C4b so that they no 
longer function in the classical or alternative pathway oonvertases 
(3, 4, 5) (Figures 1, 2). Secondly, there is a natural decay of some 
of the enzymes generated during complement activation, through loss of 
one of the t�-.0 proteins which form the oonvertase. For example, C42, 
the classical pathway oonvertase, is an enzyme with a half-life of 10 
minutes at 30°C due to decay of C2 (6) • In a similar manner, factor 
B, which is part of the alternative pathway oonvertase, C3bBb, decays 
from the oonvertase with a half-life of 4.5 minutes at 30°C (7). The 
third mechanism by which complement activation is regulated in plasma 
involves the action of proteins which either extend or shorten the 
half-life of the classical or alternative pathway C3 oonvertases. 
There are three proteins in serum which enhance the activity of the 
classical or alternative C3 oonvertases. Properdin or P is a normal 
plasma protein consisting of four nonoovalently bound subunits which 
7 
slCMs the decay of C3bBb (8) • C3 nephritic factor, or C3 NeF, is an 
autoantibody found in serum from same patients with membranoprolif­
erative glomerulonephritis. C3 NeF reacts with the alternative path­
way convertase; it also slCMS the rate of decay of the alternative 
pathway convertase (9, 10). An analogous autoantibody against the 
classical pathway C3 convertase which stabilizes the classical C3 con­
vertase has also been recently reported in serum from patients with 
systemic lupus erythematosus (ll, 12). Conversely, there are two pro­
teins in serum which decrease the activity of the classical or alter­
native C3 convertases. C4 binding protein, or C4bp, acts as a cofac­
tor for factor I in the cleavage of hemolytically active C4b to inac­
tive C4bi, as well as causing accelerated decay of C2 from EAC42 (13, 
14) (Figure 1). SlH, or factor H, analogously, acts as a cofactor for 
factor I in the cleavage of hemolytically active C3b to inactive C3bi, 
as well as causing accelerated decay of factor B from EAC3bBb (15, 16) 
(Figure 2). 
Although lysis of the target is possible via the terminal comple­
ment sequence, the central biologic impact of complement activation 
takes place with C3. A more detailed examination of C3 is therefore 
warranted. Inti ally, cleavage of C3 was thought to take place in 
three steps. First, either the classical (Cl42) or alternative 
(C3bBb) pathway convertase cleaves C3 into two fragments, C3b, which 
has a molecular weight of 171,000 daltons, and C3a, which has a molec­
ular weight of 8,900 daltons (Figure 3). C3a has anaphlytoxin activ­
ity (17). C3b, once formed, has a transient ability to react with 
cell surfaces, soluble proteins, etc; inactivation of that reactive 
Figure 3. Cleavage of C3 by classical or alternative pathway C3 
convertase. 
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site is the result of reaction with water (18, 19). A covalent ester 
bond is fonned between C3b and a surface (18, 19): C3b on the surface 
then functions in either the classieal or alternative pathway conver­
tases. Loss of C3b activity in either convertase was intially as­
cribed to C3b inacti vator, rt::M krt:Mn as factor I, which was thought to 
cleave C3b into tw:> fragments, C3c and C3d (4, 20). Neither fragment 
could participate in further C3 cleavage or cleavage of CS, the next 
cxrnponent of the canplement cascade, therefore halting the canplement 
sequence at that point. Later a cofactor for factor I was described 
by Whaley and Ruddy (16) \\tlich was recognized as a previously isolated 
serum protein of unkrt:Mn function, GlH. SlH, rt::M called factor H, 
functions in two ways to regulate the alternative pathway. As men­
tioned above, factor H causes accelerated decay of factor B from the 
alternative pathway convertase EAC3bBb (16); it also potentiates the 
activity of factor I in cleaving C3b bound to cells by either the al­
ternative or classical pathway (15). Factor H is absolutely required 
for cleavage of fluid-phase C3b by factor I (21). The effectiveness 
of factor H on the alternative pathway C3 convertase is a critical 
component in distinguishing surfaces which support the alternative 
pathway. Sheep erythrocytes ordinarily do not activate the alterna­
tive pathway. However, treatment of sheep erythrocytes with neuramin­
idase generates cells which are then able to activate the alternative 
pathway convertase (22, 23, 24). The C3b on neuraminidase treated 
sheep erythrocytes no longer interacts effectively with factor H; thus 
the feedback loop illustrated in Figure 2 is operative. This accounts 
at least in part for the "nonspecificity" of alternative pathway 
11 
act;i vation, in that the surface of the particle in some manner oon­
trols the accessibility of C3b to factor H and subsequent alternative 
pathway activation. 
Mbce recently, another intermediate in C3 cleavage has been de­
tected. Factors I and H are 'flOII k'flOIIn to result in an intermediate, 
C3bi, in which two peptide bonds of the <l chain has been cleaved 
(Figure 4). Another enzyme such as trypsin, plasmin or elastase then 
cleaves C3bi into the previously recognized fragments C3c and C3d (25, 
26). 
Receptors for C3 and its cleavage products have been recognized 
for nearly 30 years. In 1953, Nelson described a receptor on human 
erythrocytes for the initial cleavage product of C3 (27). This recep­
tor for C3b is responsible for the phenomenon known as immune adher­
ence and is present on primate erythrocytes and nonprimate platelets. 
Subsequently, receptors for C3b were described on a number of .other 
cell types (Table 1). !Ulynorphonuclear leukocytes (PMN) (28), B 
lymphocytes, macrophages (29) and monocytes (30) were all found to 
have C3b receptors. Visceral epithelial cells of the renal glomerulus 
(31), and mast cells (32) were most recently found to bear C3b recep­
tors. C4b can also serve as a ligand for the C3b receptor on several 
of these cells, including human erythrocytes (33) as well as B lymph­
ocytes, granulocytes and monocytes (34). Same B lymphocytes also bear 
receptors for the final cleavage product of C3, which is C3d (35). 
Upon recognition of the C3bi step, the cell types previously thought 
to bear C3b and/or C3d receptors, such as B lymphocytes, have. been 
reexamined for receptors for C3bi and/or C3d. CUrrently, some B 
Figure 4. Cleavage of C3b following treabnent with factors H, I, 
and/or protease. 
12 
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TABLE 1 
PRESENCE OF COMPLEMENT RECEPTORS ON SELECTED HUMAN CELL TYPES 
CELL TYPE C3b C3bi C3d C4b factor H 
Erythrocyte +, 27 -, 36 -, 36 +, 33 ND 
B lymphocyte +, 29 +, 36,37 +, 36,37 +, 35 41 
Monocyte +, 30 +, 36,37 -, 37 +, 34 NO 
Neutroph i 1 +, 28 +, 36,37 -, 36,37 +, 34 NO 
Glomerular +, 31 +, 36 -, 36 ND ND 
Epithelial Cell 
Mast ce 11* +, 32 +, 44 -, 44 ND ND 
Raji cell -, 37 +, 44 +, 44 -, 44 NO 
ND = not done. * Studies available only in rats. 
-
..,., 
15 
lyrrg;tlocytes are thought to bear C3b, C3bi and C3d receptors, while 
m:>nocytes, EMNs arrl glanerular epithelial cells have only C3b and C3bi 
receptors (36, 37). 
In addition to these oorrnal cells, a number of lymphoblastoid 
cell lines have receptors for the various forms of C3. A receptor for 
C3 and its cleavage products on Raji cells, a line orignally derived 
fran a Burkitt's lymphana in 1965 (38), was first described by Theo­
filopolous, Bokisch and Dixon (39). 'lbese receptors, unlike those 
found on normal B lymphocytes, do not interact with C4b (40). It is 
now thought that Raji cells bear two distinct receptors, one for C3bi, 
arrl one for C3d. The variable amounts of C3b resetting observed by 
different investigators may be explained by the report that these . 
cells and normal B lymphocytes release endogenous factor I when ex­
posed to C3b-bear ing cells in the presence of small am::>unts of factor 
H, thereby converting C3b to C3bi ( 41) • These same workers also pre­
sent evidence for a receptor for factor H on Raji cells. Another pos­
sible explanation for variable C3b-dependent rosettes may be found in 
the description by Okuda and Tachibana of an alteration in C3b after 
treatment with factor H (42). El:ythrocytes bearing C3b treated with 
small am::>unts of factor H are subsequently able to form rosettes with 
Raji cells. Since factor H is a ccmnon contaminant of C3 prepara­
tions, this could potentially explain the variability seen in C3b­
dependent rosettes formed with Raji cells. A universal biologic role 
of receptors for C3b, C3bi or C3d has remained obscure for many years 
despite the knowledge of their role on phagocytic cells. Particle­
bound C3b prarotes phagocytosis by EMNs, (43) mast cells (44), or ac-
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tivated macrophages (45) in the absence of specific antibody. In cell 
types \Jlich do not respond to C3b alone for phagocytosis, addition of 
C3b can prO!l'Ote ingesticn by nonocytes and oormal macrophages in the 
presence of a concentration of IgG which by itself is ineffective 
(46). However, the function of the C3b receptor en ronocytes and oor­
rnal macrophages which only mediates adherence has been shown to be 
modulated in a variety of ways. In 1975 the original observation was 
made that intraperitoneal injection of thioglycollate into mice al­
tered the function of· the complement receptor so that both attachment 
and phagocytosis occurred. Later, a lymphokine was described by Grif­
fin and Griffin \Jlich affected the function of the complement receptor 
on macrophages in vitro in a similar manner (47). Other workers sub­
sequently found that culture of human peripheral blood monocytes for 
seven days in the presence of serum but in the absence of any other 
kind of stimulant also led to phagocytosis as well as adherence medi­
ated by the oomplement receptor (48). The mechanism by W!ich the 
function of the complement receptor on ronocytes and macrophages is 
changed from one of adherence to one of adherence and phagocytosis is 
oot clear. Phagocytosis by these cells might be due to either in­
creased numbers of receptors or expression of a different type of com­
plement receptor. No evidence to support or refute these possibili­
ties has been published. A third possibility is supported by evidence 
presented by Griffin and Mullinax which suggests strongly that altera­
tion .in the function of the complement receptor on macrophages is due 
to increased receptor robility, rather than increased numbers or dif­
ferent types of receptors (49). They found that macrophages treated 
17 
with lymphokine or macrophages elicited with thioglycollate, both of 
which can mediate phagocytosis, localized all of their receptors for 
complement to immobilized surfaces bearing complement. In contrast, 
untreated or normal macrophages did not localize their receptors to 
these surfaces and retained the ability to form rosettes with eryth­
rocytes bearing complement. Thus, the function of the C3b receptor on 
monocytes and macrophages varies with the physiologic state of the 
cell. It is consistently expressed but a connection with phagocytosis 
varies. For all of these cell types, (i.e. PMNs, monocytes, macro­
phages and mast cells), C3b plays a critical role in host defense 
against a variety of organisms by mediating increased adherence of 
offending organisms to leukocytes and in same cases phagocytosis by 
these cells. 
The function of the C3b receptor on B lymphocytes has also been 
the subject of investigation for several years. In 1972, Pepys re­
ported that mice depleted of C3 by treatment with cobra venom factor 
(CVF), showed an impaired inrnune response to the T cell dependent an­
tigen, sheep erythrocytes, while their response to a T cell independ­
ent antigen, polyvinylpyrrolidone, was unaltered (50). 0JF, the cobra 
equivalent of C3b, forms a 0JF-factor B convertase which is very sta­
ble, both in intrinsic decay and regulation by the mammalian serum al­
ternative pathway proteins, factors I and H. Therefore, 0JF'Bb cleaves 
all available C3 into C3b (51). Injection of appropriate amounts of 
0JF into animals leads to depletion of C3 to less than 5% of normal 
levels for several days. Later, Waldmann and Lachmann found no re­
quirement for serum (serving as a source of complement) for in vitro 
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antibody formation (52) • The addition of human serum depleted of fac­
tor I, which contains high levels of C3b, also did not alter in vitro 
antibody formation by spleen cells. Both of these results provide ev­
idence that argues against an abrolute requirement for C3 in antibody 
formation in vitro. Waldmann and Lachmann attributed in vitro effects 
of CVF on antibody formation to contamination of CVF with phospho­
lipase which is also present in cobra venom. The effects of CVF in 
vivo may however, be due to effects of complement depletion on antigen 
localization and cyolical peaks of antibody production. (53, 54) In 
any case, tl1e apparently normal inmunoglobulin levels and antibody re­
sponse to specific antigens seen in genetically C3-deficient individ­
uals precludes a necessary role for C3 and/or its degradation products 
in antibody responses (55). C3 and/or its fragments may play a regu­
latory role in lymphocyte function. Several reports have found that 
fragments of C3, i.e. C3a, C3b, C3c and C3d, inhibited blastogenesis 
of lymphocytes in response to specific antigens but had no effect on 
_their response to rnitogens (56, 57, 58). It is not conclusively es­
tablished that these effects are mediated through the C3b receptor on 
B lynphocytes, since antibody to the C3b receptor has not been tested 
for its influence. In this case, C3 cleavage products appear to play 
a negative regulatory role. Evidence for a positive role includes the 
production of a lymphokine by B lymphocytes incubated with C3b. These 
cells produced a monocyte chemotactic factor in the absence of cellu­
lar proliferation (59). Later ��rk by the same group of investigators 
showed that C3b was the only fragment of C3 which induced lymphokine 
production. C3a, C3c and C3d failed to induce lymphokine (60). The 
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d:>servation that lymphokine is produced by B lymphocytes which possess 
C3b receptors and is not produced by T lymphocytes which do not is 
consistent with a role for the C3b receptor in production, but in no 
way proves it. 
Chemical characterization of the C3b, C3bi or C3d receptors has 
thus far been limited. It has been knCMn for sane time that the C3b 
receptor on eryth(ocytes and leukocytes is trypsin sensitive (28, 
29). The importance of disulfide groups for the function of cample-­
nent receptors on Raji cells for rosette formation has also been de-­
IIOnstrated (61). However, cnly tv.u instances of solubilization of 
membranes leading to a fraction maintaining complement receptor func­
tion have been reported. In 1975, Dierich and Reisfield solublized 
isolated membranes from Raji cells with 2 M KBr and found that both 
intact membranes and a high salt extract from membranes inhibited C)­
dependent rosette formation (62). Approximately 400 ng/ml of solu­
bilized material caused a 50% inhibition of rosettes. In 1976, Okuda 
and Tachibana solubilized human erythrocyte ghosts with Nonidet P-40 
(NP-40) and adsorbed solubilized material to C3b-bearing cells (63). 
Material which eluted from the C3b-bearing cells could agglutinate C3b 
but �ot C3d bearing cells. Perhaps due to the relative insensitivity 
and semiquantitative nature of both inhibition of rosettes and hemag­
glutination as assays, no further work on characterization of oample-­
nent receptors was published for some time. 
During the years when complement receptors were being found on 
various cell types, Hoffman (64) observed inhibition of a::rnplement ac­
tivity by solubilized human erythrocyte membranes. Using the cample--
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rrent technology available at the time, he found that the extract of 
erythrocyte membranes accelerated the rate of decay of the C42 conver­
tase (65). In 1979, Fearon described and isolated a glycoprotein 
(gp205) (66) with a I!Olecular weight of 205,000 daltons fran hlllllan 
erythrocyte membranes which accelerated factor B decay from EAC3bBbP 
and served as a cofactor for factor I in the cleavage of fluid-phase 
C3b. Antil:xx]y to gp205 was later shown to blcx::k formation of rosettes 
b etween EX::Jb and hlllllan erythrocytes, ruNs, B lymphocytes and monocytes 
(67). Fran this it was inferred that gp205 is the C3b receptor. 
Fearon also demonstrated that anti-gp205 precipitated similar molecu-
lar weight glycoproteins from all of these cell types. Other investi­
gators have confirmed Fearon's finding that anti-gp205 blcx::ks C3b­
dependent rosette·formation (37). The separate identity of the C3bi 
and C3d receptors was then much easier to demonstrate utilizing anti-
gp205. Dobson et al found that anti-gp205 was unable to blcx::k com­
pletely rosetting due to C3bi and C3d on B lymphocytes, monocytes, 
PMNs and Raji cells. 
Another approach to the C3b receptor was used by Gerdes, Klatt, 
and Stein (68). High salt extracts fran tonsil cells similar to those 
prep�ed from Raji cells by Dierich and Reisfield were adsorbed onto 
rabbit C3b-coated sheep erythrocytes and used to inmunize rabbits. 
After extensive adsorptions, their antiserll!ll retained the ability to 
blcx::k C3b-and C3d-dependent rosette formation. Immunoprecipitates 
fran both tonsil cells and erythrocytes yielded three peaks with ap­
parent molecular weights of greater than 1 x 106, 80,000 and 60,000 
daltons. Upon reduction two new peaks of 38,000 and 18,000 daltons 
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were observed (69, 70) The discrepancy between their early results 
an1 those of other investigators was reoolved in a recent report in 
which another method of membrane isolation yielded a 205,000 dalton 
immunoprecipitate similar to gp205 (71). The relation of the 205,000 
dalton immunoprecipitate to their earlier smaller fragments was not 
completely clear, although proteolysis was implicated. 
After the initial description of gp205 and its influence on the 
alternative pathway, work on its other effects has been undertaken. 
Since C3b receptors· also bind C4b, Iiada and Nussenzweig isolated 
gp205 and tested it for its effects on C4b (72). TWenty percent of 
labeled gp205 bound to EI\Cl4 whereas only 3% bound to Wlel alone. 
Additionally, uptake of labeled gp205 on WIC14 could be lowered by 
increased anounts of C2. However, gp205 had no effect on WIC14 bear­
ing limited anounts of C4 in the presence of excess C2. Therefore, 
gp205 functions in the classical pathway by competing with C2 for 
binding to C4b. Gp 205 also serves as a cofactor for factor I in the 
cleavage of fluid-phase C4b, as does C4-binding protein, a factor 
analogous to factor H of the alternative pathway. Gigli and Fearon 
have independently confirmed these results (73). 
The function bf gp205 on cell surfaces has also been the subject 
of recent investigations. Obviously, a membrane receptor for C3b 
which also has the capacity to avoid the potential biological hazard 
of host cell surface oamplement activation by accelerating the decay 
of the classical and/or alternative C3 convertases would be of great 
value. Another function of gp205 has been recently deiJPnstrated in 
which gp205 mediates adsorptive endocytosis, much like the low density 
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lipoprotein receptor (74). Fearon, Kaneko and 'lbomson found that 
anti-gp205 (Fab')2 but not (Fab') as well as the labeled ligand, 
C3b-OR (C3b covalently attached to sheep erythrocytes) were inter­
nalized by PMNs at 37 C (75) • This mechanism could be very important 
in clearance of imnune cx::mplexes bearing C3b. C3b receptors on macro­
phages were found to be important in clearance of immune complexes 
bearing cx::mplement in vitro. Trypsin treabnent of macrophages, which 
eliminates the cell surface C3b receptor, resulted in lower amounts of 
clearance by macrophages (76). 
Only one report of isolation and characterization of the C3d 
receptor has been published (77). A glycoprotein of 72,000 daltons 
isolated from 15 liters of spent Raji cell media has specific binding 
to C3d and not C3b. (Fab') 2 antibody to this glycoprotein bound 
cnly to B lymphocytes and not to T lymphocytes, monocytes or PMNs. 
The antibody also blocked 100% of C3d-dependent rosettes on B lympho­
cytes, Raji cells or Daudi cells, whereas it only blocked 50% of ro­
settes formed with C3bi-coated ce:p.s. The residual 50% binding in the 
presence of this antibody is presumably due to a separate membrane 
component specific for C3bi, which does not recognize C3d. 
In order to determine whether diverse cell types expressed simi­
lar components which regulated complement function, a horrogenous cell 
line bearing cx::mplement receptors, Raji ceils, was examined for the 
presence of activity resembling gp205 and other control proteins on 
the alternative pathway. For cx::mparison purposes, mononuclear cells 
from tonsils were used as a source of gp205. TWo sources of Raji 
cells did bear a membrane cx::mponent which inhibited alternative 
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pathway lysis and caused accelerated decay of �43bBb. Some inhibi­
tion of alternative lysis and accelerated decay of. the alternative 
pathway convertase by membrane components of Raji cells was clearly 
due to a component distinct from gp205, whereas inhibition by membrane 
components prepared from tonsil cells was entirely due to gp205. 
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MATERIAlS liND MEJ.'HODS 
Reagents and Buffers 
All reagents and buffers and their sources are found in the Ap­
pendices. Any chemical used whose source is not listed was obtained 
from Fisher Scientific, Pittsburgh, Pa. 
Cellular Intermediates 
Sheep erthrocytes (E) were collected in Alsever 's solution and used 
after 1 week at 4°C; E were diluted in gelatin veronal buffer with 
0.01 M disodium ethylenediamine tetraacetate (0.01 M �/GVB) and 
centrifuged at 800 x G for 5 minutes, after which the supernate was 
renoved. These two steps were repeated until oo !lPre henolysis was 
present in the supernate. E were then resuspended in 0.01 M EDTA/GVB 
at 1 x 109 /ml and incubated at 37"c. An equal volume of rabbit 
antiserum containing IgG antibody to sheep E diluted 1:175 or 1:200 in 
0.01 M �/GVB was added dropwise. Greater concentrations of 
antiserum resulted in irreversible agglutination of erythrocytes. 
After 1/2 hour at 37°C, erythrocytes with antibody, (�),were cen­
trifuged at 800 x G for 5 minutes, washed once with veronal buffered 
saline with gelatin (GVB++) and used for all subsequent steps. All 
further cellular intermediates except EAC43 were generated using vero­
na! buffered saline with gelatin and dextrose (DGVB++). 
EAC43 were prepared using a serum reagent, R3, depleted of late 
complement components as described by Lachmann and Hobart (78). R3 is 
a serum treated with zymosan which depletes it of approximately 50% of 
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C3 and sufficient C5 to prevent terminal pathway lysis. R3 was pre­
pared by incubating nonnal human serum at 37°C for 30 minutes with 
0. 75 mg/ml of zyrrosan. After centifugaticn at 800 x G for 5 minutes, 
serum was rerroved and used to generate EIIC43. FA at 2 x 108/ml in 
veronal buffered saline with gelatin (GVB++) were reacted for 2 
minutes at 37°C with a 1:10 to 1:60 dilution of R3 reagent. Varying 
concentrations of R3 were used for irrlividual preparations of EIIC43 
deperrling on the amount of residual C5 present. Suramin sodium, an 
inhibitor of factor I, was added to a final concentration of 1 mg/ml 
and incubated with the erythrocytes for an additional 2 minutes at 37° 
c. Cold gelatin veronal buffered saline with 0.04 M EDTA (0.04 M 
ID'ffi/GVB) was added and EI\Cl423 were centrifuged and washed once. 
Residual Cl was rerroved and C2 was decayed from the EIIC43 by incuba­
tion in 0.04 M ID'ffi/GVB at 37°C for 2 hours. The resultant EIIC43 
lysed in the presence of factors B and D and a source of terminal com­
plement canponents. 
EIIC4 were prepared as descri9ed by Borsos (79), frozen in glyc­
erol at -70°C (80), and were the gift of Dr. S. RuddY. EI\C4 were 
thawed in the folla-�ing manner. An aliquot of approximately 4 x 109 
EI\C4 in 0.8 ml was placed in a 37°C water bath and allowed to thaw. 
0.23 ml of 50% dextrose in saline was added dropwise and incubated 5 
minutes at 37°C. 11 ml of prewarrned mannitol/qvB++ was then added 
dropwise over a 9 minute interval at 37°C, followed by an additional 
35 ml. of prewarrned DGVB++ over an ll minute time period. FAC4 were 
then washed with DGVB++ until no hemoglobin was visible in the su­
pernate and resuspended to 1 x 108/ml in DGVB++. They could then 
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be used for Cl titrations. 
E1\Cl4 were prepared by mixing equal volumes of EAC4 and guinea 
pig Cl at 400 units/ml. After incubation at 30°C for 15 minutes, 
E1\Cl4 were centrifuged, washed, and resuspended at 1 x 108 /ml. 
These cells could then be used for C2 titrations. For preparation of 
E1\Cl4°xy2, 10,000 units of human C2 in 0.1 ml were oxidized with 0.1 
ml of a 1:200 dilution of potassium iodide reagent in 0.1 M phosphate 
pH 6.0 (6) for 5 minutes at room temperature and added to EAC14 at 30° 
C. After 15 minutes, EAC14°xy2 were centrifuged, washed and resus­
pended at 1 x 108/ml. 2 ug of C3 were added to EAC14°xy2 at 30°C 
am incubated for 15 minutes followed by one wash. 
Generation of Zymosan-c3bBbP 
Zymosan (2 mg/ml) was incubated with normal human serum diluted 
1:3 in r:GVB++ for 10 minutes at 37°C. Zymosan was rerroved by 
centrifugation and incubated for 2 hours at 37°C in 0.04 M ED�GVB to 
rerrove Cl, C2 and factor Bb (ZXd2). Alternative pathway convertase 
was placed on 0.5 mg of ZXd2 with �e addition of 10 ng of factor D, 
2.25 ug of 125r factor B and 2.5 ug of properdin in 0.5 ml of 
�++ during a 30 minute incubation at 30°C. The uptake of 125r 
factor B onto zymosan was 4.5% of input. After centrifugation and one 
wash in r:GVB++, zymosan was then incubated with either veronal buf-
fered saline (VBS) or test materials in VBS. The radioactivity re-
maining on the zyrrosan was used to quantitate decay of factor B in the 
presence of various test materials. 
Herrolytic Titration of Complement Oomponents 
A single damaged site on the membrane of a cell is sufficient for 
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lysis, so that for large numbers of cells, the probablity of lysis 
follows the Poisson distribution. This is the theoretical basis for 
all complement titrations which are designed such that only one com-
ponent is in limiting supply and all others required for lysis are 
present in at least 100 fold excess. All lysis above reagent lysis is 
therefore due to the quantity of the limiting reagent being tested. 
The average number of hemolytic sites per cell is given by the follow-
ing expression: z = - ln ( 1 - y ) where y is the fraction of cells 
lysed, and z is the average number of hellPlytic sites per cell (81). 
A value of 1 Z of hellOlytic activity is 63% lysis. The titer of a 
reagent is the reciprocal of the dilution of reagent which results in 
63% lysis or 1 z. 
The absorbance of hellPglobin in the supernate of each tube at 414 
nm was used to quantitate the allPunt of lysis (A414> and used in the 
calculations for z as described above. All assays included the fol-
lowing controls: 100% lysis (cells plus 1.8 ml distilled water), cell 
blank (CB) (cells �lith 0.3 ml of 0.04 M ID'm), reagent blank (RB) 
(cells with 0.3 ml of rat serum in 0.04 M ED'I2\ but no factors B and 
D), and a::uplement color (CC) (no cells and 0.3 mls of rat serum in 
0.04 M ED'I2\). Calculations, using the controls described above, for 
the average number of sites per cell used the following formulas: 
corrected 100% lysis (calculated) 
100% lysis <�14) - ( CC �i4 + CB A414 ). 
y = experimental lysis (A 414 ) - ( CC A 414 + CB A 414 
corrected 100% lysis (calculated) 
reagent lysis = RB (A 414 )-( CC A 414 + CB A 414 
corrected 100% lysis (calculated) 
Z=-ln( l-y) 
reagent z = - ln ( 1 - reagent lysis 
corrected z = z - reagent z. 
C orrected z were then used as z recorded. 
Inhibition of Alternative Pathway Lysis 
In order to detect inhibition by test materials of lysis of 
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EAC43bBb, preliminary titrations of factor B were performed for incH-
vidual preparations of �43 in the presence of excess factor D and 
C5-C9. EAC43 (107 cells in 0.1 ml of rx;vB++) were iocubated with 
amounts of factor B varying from 0.25 ng/ml to 1 ug/ml and 400 ng/ml 
of factor D for 15 minutes at 30°C. �43bBb were then incubated with 
0.3 Bu. of rat serum diluted 1:15 in 0.04 M ED'm/GVB for one hour at 37° 
C which was used to supply excess CS-c9 (C' .ED':m). In inhibition ex­
periments, �43 were first incubated at 37°C with 0.1 ml of test ma­
terial containing membrane extract or C3b control proteins in rx;vs++ 
or DGVB++ alone. After 1 hour, except in time course studies, 400 ng 
of factor D and a amount of factor B which resulted in 40-90% lysis as 
determined from preliminary titrations was added in 0.1 ml of 
DGVB++. This arrount of factor B varied from 1.2 ng/ml to 797 ng/ml 
for various preparations of �43 and was presumably due to variation 
in the arrounts of C3b an �43 which could function in the alternative 
pathway from time to time. After 15 minutes at 30°C, 0.3 ml of rat 
serum in 0.04 M ErmVGVB was added as described above (C' .ED':m). 
After 1 hour at 37°C, 1.5 ml of 0.15 M NaCl was added to each tube. 
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'lhe tubes were centrifuged and the anount of henolysis determined 
spectrophotanetrically at 414 nm. In inhibition experiments, a "solo" 
control containing no inhibitory material plus factors B and D was 
in:::luded. Inhibition of herrolysis was quantitated by the empirical 
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relationship Z' where Z' = ln ( 1- decimal fraction of inhibition ). 
Dilutions of inhibitor were plotted versus Z' and the reciprocal dilu­
tion where Z' = 0.5 was used as the titer of inhibitor. 
Hemolytic Synergy Experiments 
�4°xy2 prepared as described above were incubated with 2 ug/ 
ml of C3 which resulted in approximately 50% lysis (limited) in the 
presence of excess CS-c9. �4°xy23 with limited C3 were incubated 
for one hour at 37 C with various inhibitors. 0.1 ml of CS at 100 
units/ml and 0.1 ml of guinea pig R345 at 1:120 were added for 1 hour 
at 37°C. R345 is a guinea pig serum reagent treated with potassium 
thiocy?"ate (KQIS) to deplete it of C3, C4 and CS (82). 
Decay of Classical and Alternative Pathway C3 Convertases 
Decay of factor B from EAC43bBb was detected using amounts of 
factor B as given in individual experiments which caused 50-90% lysis 
at 0 minutes of decay. EAC43bBb were centrifuged and resuspended in 
test material or VBS which was diluted in 0.01 M ED'ffi/GVB. Aliquots 
of 107 cells·were removed at various intervals and added to 0.3 m1 
of rat serum to detect the inhibition of lysis of EAC43bBb. The half 
life of the convertase (t 1/2) was determined graphically by plotting 
log10. Z versus time. Decay of C2 was determined using quantities of 
C2 resulting in 50-90% lysis at 0 minutes of decay. Decay of EAC142 
in the presence of test material or buffer, detection of lysis using 
rat sennn, and t 1/2 determinations were performed exactly as 
described for factor B decay. 
Generation of C3bi 
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C3b at 1 mg/ml in verona! buffered saline with 2.5% dextrose 
(D\IBS++) was incubated with 1 ug/ml each of factors H and I for 24 
hours at 37°C with 0.05 % sodium azide (83). It was then adsorbed 
with 1 ml of anti-factor H Sepharose at room temperature for 10 mi­
·nutes and filtered over glass wool. The amount of anti-factor H used 
adsorbed 10 ug of purified factor H. By itself, C3bi had no influence 
on decay of EI\C43bBb. 
Affinity Chromatography 
One volume of Sepharose Cl-4B was washed three times in distilled 
water and resuspended in distilled water to make a 50% suspension. 
cyanogen bromide (0.15 gm/ml of packed Sepharose) was dissolved in an 
equal volume of hot distilled water and added to the Sepharose suspen­
sion. 'fue mixture was maintained with stirring between pH 10.5 and ll 
with 4 N sodium hydroxide (NaOH). After the pH no longer rapidly 
decreased, 30-50 volumes of cold 0.1 M sodium bicarbonate (NaHC03) 
pH 8.0 and ice were added and the suspension filtered over a Whatman 
number 1 filter. For small amounts of Sepharose, the suspension was 
rapidly centrifuged. The "activated" Sepharose was then added to one 
volume of a protein solution and rocked overnight at 4•c. Antibody 
solutions had been previously dialyzed versus VBS; all other protein 
solutions had been dialyzed versus 0.1 M NaHC03 pH 8.0. In general, 
protein concentrations were 5-15 mg/ml. The following day, Sepharose­
protein was washed three times with 0.1 M NaHC03 and resuspended in 
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1 volume of 1.0 M rronoethanolamine pH 8.0 for two hours with rocking 
at roam temperature. The Sepharose-protein solution was then washed 
three times with the following: 
0.1 M sodium acetate 1.0 M NaCl at pH 4.0 
0.01 M Tris-HCl 1.0 M NaCl at pH 8.0 
0.01 M Tris-HCl 0.15 M NaCl 0.01 M ED� at pH 8.0 
Following these washes, the Sepharose-protein conjugate was washed in 
the relevant buffer for its use. Between 50-90% of the protein solu­
tion was routinely bound to the Sepharose-Cl-4B. 
Inhibition of Rosettes 
Fifty ndcroliters of �43 which bear both C3b and C3bi at 4 x 
108/ml in GVB++ were ndxed with 0.2 ml of _VBS or dilutions of test 
material in VBS and incubated at 37°C for 15 ndnutes. Subsequently, 5 
x 105 Raji cells in GVB++ were added in 0.05 ml and incubated 30 
;m_nutes at 37°C followed by an addditional 10 minutes on ice. Each 
suspension was rerroved and 100-200 Raji cells examined microscopically 
for rosette formation with �43. A positive rosette consisted of 3 
or rrore sheep cells around a Raji cell. In all experiments given in 
the Results, the percent rosettes in VBS alone was between 40 and 45%. 
Raii Cells 
Raji cells were obtained from Dr. Chen at the University of North 
carolina (Raji CN) or fran the American Type CUlture Collection (A'IXX::) 
through Dr. Daniel Conrad, (Raji OC). A number of other Raji cell 
lines were also used in selected instances and their sources given in 
the Results. Raji cells were kept in continuous culture in stationary 
flasks using RIMI 1640 supplemented with 5% fetal calf serum (FCS) and 
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5% newborn calf serum (NBCS), penicillin at 100 units/ml, streptomycin 
at 100 ug/ml and amphotericin B (Fungizone) at 250 ng/ml. Spinner 
cultures were established with Raji cells at 1-2 x 105;m1 and cul­
tured for 4-6 days to a final cell density of 1-2 x 106/ml. 
Subculture of Raji DC old Cell Line by Dilution 
Raji cells were plated in 96 well Costar plates at an average of 
2 cells/well in conditioned medium (CM). CM was generated by 24 hours 
of culture of Raji cells at 1 x 105 /ml. CM was filtered through a 
0.22 micron Milipore filter before use. The Raji cells in plates 
were allowed to grow for 2 weeks with additions of CM at 2-3 day in-
tervals. ll3 of 192 wells (58%) showed growth after 1 week. 20 of 
the fastest growing cell lines were expanded in 24 well plates and 
eventually used to establish cell lines. 
Tonsil Cells 
Tonsils were obtained from patients undergoing routine 
tonsilectany through Dr. T. Mohanakumar in the Department of Surgery 
at the Medical College of _Virginia. Tonsils were macerated on a metal 
screen and small fragments and cells washed through with RPMI 1640. 
Large aggregates were alla.-1ed to settle at 1 x G for 5-10 minutes. 35 
mls of cells at approximately 1 x 108/ml were layered over 15 mls of 
Ficoll-Hypaque and mononuclear cells isolated by density centrifuga-
tion (84). The monolayer was removed and washed three times with RPMI 
1640 before freezing at -70°C at 2-5 x 108/ml. 
Membrane Preparation 
CUltures of spinner flasks of Raji cells containing 1-4 x 109 
cells were centrifuged and washed three times in RPMI 1640. Tonsil 
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cells were thawed and 1-10 x 109 cells were used to prepare mem­
branes. The cells were lysed using e ither hypotonic lysis (85) or in 
the case of frozen cells using nitrogen cavitation (62). Briefly, 
viable cells were resuspended in 10 mls of IUMI and incubated at 37°C 
for 5 minutes. 1.67 ml of 90% ·glycerol (v/v) in IUMI was added tO the 
cells and incubated at 37°C for 5 minutes. 'Ibis step was repeated 
twice and the final cell suspension in:::ubated for an additional 5 mi­
nutes on ice. It was then centrifuged at 800 x G for 10 minutes at 4° 
c. After renoving the supernate, the cell pellet was disrupted using 
a vortex and lysed by the addition of 13 mls of 0.01 M Tris-HCl with 1 
11M MgC12 and 1 mM cac12 at pH 7. 4. After an in:::ubation of 5 mi-
nutes on ice the suspension was centrifuged at 800 x G for 10 minutes 
at 4°C. '!be supernate was rem::>ved and an additional 13 mls of Tris­
HCl buffer added and incubated with remaining cells for 5 minutes on 
ice. After another centrifugation at 800 x G for 10 minutes, the two 
supernates were combined and centrifuged at 3200 x G for 10 minutes to 
pellet mitochondria and lysosomes. The ho!rogenate was removed with a 
Pasteur pipette, diluted to 33 mls with.additional Tris-HCl buffer and 
placed in a nitrocellulose tube. 5 mls of 38% sucrose was carefully 
layered underneath the homogenate. After centrifugation at 95,000 x G 
for 90 minutes at 4°C, the cytosol was removed and about 5 ml of the 
interface =ntaining crude rnenbranes was o btained. M=mbranes were 
pelleted at 180,000 x G for 30 minutes at 4°C. Potassium bromide 
(KBr) extraction of isolated membranes was performed with the addition 
of 5 ml of 2 M KBr with 0.01 M N-2-hydroxyethylpiperazine N-2-ethane­
sulfonic acid (HEPES) and 1 reM MgC12 at pH 7.4 for 30 minutes at 4°C 
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en a rocker. Insoluble residue was renoved by centrifugation at 
lBO,OOO x G for 30 minutes at 4eC. In scme experiments less than 5 m1 
of 2 M KBr was used for extraction. This was performed in experiments 
where more concentrated preparations of inhibitor were required, i.e. 
gel filtration and testing of KBr extracts from various cell lines 
using less than 1 x 109 cells. In these cases insoluble material' 
was renoved by centrifugation at 4B,OOO x G for 1 hour. For all 
experiments except gel filtration, extracts were dialyzed overnight 
versus VBS and the resultant insoluble residue dispersed throughout 
the solution before use. Membranes from tonsil cells were prepared in 
an analagous fashion except that cells were disrupted with nitrogen 
cavitation. Thawed cells were placed in a nitrogen bcrnb at BOO pounds 
per square inch for 20 minutes and the pressure released. The disrup­
ted cells were collected and centrifuged at BOO x G for 10 minutes to 
renove intact cells. Supernate was then centrifuged at 3200 x G for 
10 minutes to reoove any remaining intact cells and nuclei. Membrane 
preparation and extraction was then identical to that described above 
for Raji cells. In one experiment, tonsil cell membranes were ex­
tracted with 1% Nonidet P-40 (NP-40) in VBS overnight at 4°C rather 
than in the 2 M KBr buffer. 
Gel Filtration 
A 1 x 60 em column of Sephacryl 200 or 300 was used to estimate 
oolecular weight of inhibitory material fran KBr extracts of both Raji 
and tonsil cells. The column was equilibrated in 2 M KBr with 0.01 M 
HEPES or in VBS with 0.1% NP-40. Extract (0.6 ml) was added and elut­
ed fran the column by pumping 2 M KBr with 0.01 M HEPES or VBS with 
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0.1% NP-40 at 1-2 ml/hr. One ml fractions were =llected. Protein 
concentration was measured by determining optical density at 280 nm or 
by a modified Lowry determination (86) for fractions =ntaining 
NP-40. Fractions in 2 M KBr were dialyzed overnight versus VBS; 
fractions in NP-40 were diluted 1:20 in DGVB++ and both tested for 
inhibition of alternative pathway lysis. Standards to calibrate the 
=lumns were applied separately in 2· M KBr. Void volume was deter-
mined by the elution of blue dextran. Elution profiles of rolecular 
weight standards, inmunoglobulin G, chymotrypsinogen, ovalbumin and 
ribonuclease, were monitored by absorbance at 280 nm or by reaction 
with specific antisera for goat immunoglobulin or ovalbumin. Peak 
elution of each marker was used determine Kaverage (Kav). 
Kav = Ve - Vv 
Vt- Vv 
where Ve is the elution volume of the marker or peak of alternative 
pathway inhibition, Vv is the void volume of the =lumn and _vt is the 
total bed volume. Kav for each marker was plotted against the log-
arithm of rolecuar weight and the standard curve computed by linear 
regression analysis. The volume at which maximal inhibition of alter-
native pathway lysis occurred was used to determine Kav for inhibition 
and its rolecular weight was determined from the standard curve. 
Immunadsorbents and Adsorbtion Experiments 
For testing KBr extract from Raji cells, imnunoadsorbent =lumns of 
Sepharose Cl-4B beads bearing goat antibody to factor ·H and HSA were 
packed in Pasteur pipettes plugged with glass wo:>l (0.5 em x 3.5 em). 
KBr extract fiom Raji cells (0.4 ml =ntaining 94 ug of protein) or a 
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dilution of purified factor H in VBS was passed over the column by 
gravity and the column was washed with 1 m1 of VBS. 1-1.2 m1 of ef­
fluent was collected from both columns and tested for residual inhib­
itory hemolytic activity and protein. All other experiments discussed 
utilized packed adsorbents to minimize dilution of extract. Imnuno­
adsorbents of anti-factor I and anti-HSA were centrifuged and a packed 
volume (0.2 ml.) of Sepharose iocubated with 0.2 ml. of KBr extract from 
Raji cells containing 47 ug of protein or a dilution of purified fac­
tor I and allowed to react for 10 minutes at room temperature with one 
shaking. After an additonal 10 minutes, the supernate was removed, 
filtered over glass wool and again assayed for residual inhibitory ac­
tivity and protein. Similar adsorption experiments were performed 
using KBr extract from tonsil cells (0.2 ml. containing 28 ug of pro­
tein) and 0.2 m1 of packed anti-HSA, factor I or factor H. 
Blocking Experiments with Antibodies 
In same experiments KBr extracts from Raji or tonsil cells were 
preincubated at 4°C for 30 minutes alone or with various antibodies to 
gp205 or IgE. Anti-IgE was used as a control. 0.4 m1 of VBS was 
added and they were then centrifuged at 48,000 x G for 1 hour at 4°C. 
lis mentioned earlier in the Materials and Methods, KBr extracts in VBS 
have particulate material which is reJIDved by centrifugation. Pre­
liminary experiments showed that tv.D-thirds of inhibitory material in 
KBr extracts was contained in the precipitate and after resuspension 
in VBS retained its activity. 'Itlis procedure was performed at 4°C to 
avoid the influence of serum factor(s) on the capacity of the KBr ex­
tract to inhibit alternative pathway lysis as d iscussed in the Results 
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or to prevent adsorptive endocytosis of C3b receptor mediated 
by 
unbound (Fab'l2 anti-gp205 (75) in those experiments testing inhibi­
tion of rosette formation by KBr extracts. After preincubation at 4°C 
and centrifugation the supernates were renoved and the pelleted ex­
tract fragments resuspended in the original volume of VBS . These con­
trol extracts or extracts treated with antibody were then tested for 
inhibition of alternative pathway lysis or ability to inhibit forma­
tion of rosettes. 
Radiolabeling of Factor B 
The following reagents were added in order to a plastic test tube: 
1 small stirring bar 
79 ug factor B in 0.2 m1 of VBS 
.04 m1 of lactoperoxidase (LID) at 1 rng/ml 
100 UCi of Na125I 
.04 m1 of 3% H202 diluted 1:1250 in water 
The mixture was stirred gently for 5 minutes and unbound iodine sepa-
rated by gel filtration. The mixture was added to the top of a column 
of Sephadex G-25 (0.5 x 31 em) in VBS that had been pretreated with 1 
rng of BSA. Fractions of 1 m1 were collected and tested for precipi t-
ability of counts with trichloroacetic acid (TCA). 0.005 m1 of each 
fraction was added to 0.5 m1 of bovine serum albumin (BSA) at 1· rng/ml 
in VBS. After preoounting, 0.5 ml of 20% TCA was added and the tubes 
were centrifuged at 850 x G for 5 minutes. Residual soluble radio-
actiyity in 0.5 m1 of supernate was determined. The percent of radio-
activity precipitated by 20% TCA was determined by the following cal-
culation: 
TCA precipitable = 1 - Soluble counts x. 2 
Precounts 
X 100 
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Fraction 4 was 80% TCA precipitable and had a specific activity of 7.5 
x 104 counts per minute (CPM)/ug. Both unlabeled factor B and frac-
tion 4 were tested for activity using EAC43. On a weight basis frac­
tion 4 retained 31% of the hemolytic activity of the unlabeled pro­
tein. Uptake of labeled factor B onto EAC43 was 1% in 0.01 M FD'm. 
(mnspecific uptake) and 3.1% in rx;vs* in the presence of 400 ng/ 
ml of factor D (specific uptake) • 
SDS-PAGE Analysis of Fluid-Phase C3b 
In order to analyze cleavage of C3b by KBr extracts or factors I 
and H, C3b was labeled with 125I in a procedure identical to that 
used for factor B except that insoluble Lro was used. Radiolabeled 
C3b had a specific activity of 1.14 x 105 cpm/ug. Labeled C3b (1 
ug} was incubated in 0. 04 ml C>f VBS alone or in the presence of var-
ious reagents. Reagents included KBr extracts from Raji or tonsil 
cells, factor I, factor H or combinations of these. After incubation 
at 37°C for the indicated intervals, 0.16 ml of VBS and suramin sodium 
at 1 mg/ml were added to prevent further cleavage of C3b and the sarnr 
ples were dialyzed overnight versus 0.0625 M Tris-HCl pH 6.8. Elec-
trophoresis was performed on 10% acrylamide gels using the Laemmli 
buffer system (87). Appropriate amounts of 20% SDS and 2-mercapto-
ethaml (2�) were added to give a final sample concentration of 2% 
SDS and 5% 2 ME. Samples were placed in a boiling water bath for 90 
seconds and two crystals of sucrose and 0.005 ml of 0.05% bromophenol 
blue then added. Samples were run at 125 volts for approximately 2-3 
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oours. After renoval of the stacking gel, slabs· were stained for 30 
minutes in 0.5% Oocmassie blue with 25% isopropanol and 10% acetic 
acid at room temperature. They were then destained at 50-70°C with 
10% acetic acid, allowed to cool and . stirred overnite. After destain­
ing the gel was placed in 1% glycerol in 10% acetic acid for 30 mi­
nutes at roam temperature to stabilize it before being dried on a slab 
gel dryer for 90 minutes. Autoradiography was then performed by ex­
posing the dried gel to Kodak X-R-5 X-ray film at -70°C overnight and 
developed. 
Protein Determinations 
Protein concentrations were determined using a standard Lowry 
procedure as mcx:lified by Wang and Smith (B5). Bovine serum albumin 
was used as the standard. 
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RESULTS 
Influence of KBr Extracts fran Raji and 'lbnsil cells on Lysis of EAC43 
by factors B, D and C5-c9 
In view of Fearon's observations concerning the ability of gp205 
to inhibit alternative pathway dependent lysis (66), KBr extract fran 
Raji cells was tested for similar activity in the following experi­
ment. Concentrations of extract from 8-128 ug/ml were preincubated 
with EAC43 and theh 16 ng/ml of factor B and 400 ng/ml of factor D 
were added. Alternative pathway lysis was determined exactly as de­
scribed in the Materials and Methods by addition of C' EDTA. As shown 
in Figure 5, KBr extract from Raji cells produced a dose dependent in­
'hibition of the lysis of EAC43 with factors B, o, and CS-c9. At the 
concentration of 128 ug/ml the KBr extract yielded a Z' value of 0.90 
which corresponds to 60% inhibition of lysis. Loss of inhibition was 
seen when KBr extract from Raji cells was heated for 30 minutes at 56° 
C prior to addition to the EAC43. Similar results were obtained in 
another experiment. In separate experiments, KBr extracts fran tonsil 
cells were shown to possess similar activity in alternative pathway 
lysis (Figure 6). As with KBr extract from Raji cells, preincubation 
of 8. 75-140 ug/ml of KBr extract from tonsils with EAC43 produced a 
dose dependent inhibition of the lysis after addition of 24. 5 ng/ml of 
factor B, 400 ng/ml of factor D and C5-c9. At the concentration of 
140 ug/ml the extract yielded a Z' value of 2.8, which corresponds to 
94% inhibition of lysis. Loss of dose dependent inhibition of alter-
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Figure 5. Influence of KBr extract from Raji cells on lysis of 
EAC43bBb. Aliquots of KBr extract (128 ug/ml) were incubated for 
30 minutes at 0 °C or at 56°C and then diluted and tested for their 
inhibition of lysis of EAC43 incubated with 16 ng/ml of factor B 
and 40 0 ng/ml of factor D. Z' is proportional to the inhibition of 
lysis. o---o 0 °C. e------e 56°C. 
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Figure 6. 
FJIC43bBb. 
Influence of KBr extract from tonsil cells on lysis of 
Aliquots of KBr extract (1.87 mg/ml) were incubated for 
30 minutes at 0°C or at 60°C and then diluted and tested for their 
inhibition of lysis of EAC43 incubated with 24.5 ng/ml of factor B 
and 400 ng/ml of factor D. o-o 0°C. � 60°C. 
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native pathway lysis was seen when extract was heated for 30 minutes 
at 60°C prior to addition to the EAC43. Similar results were obtained 
·in another experiment. The extent of inhibition of lysis in the pres­
ence of KBr extract fran tonsil cells exceeds that seen with KBr ex­
tract from Raji cells. No arrount of KBr extract from Raji cells was 
able to cause 94% inhibition of lysis in these experiments or any 
others. This is also illustrated by comparing inhibition of lysis by 
both extracts at a concentration of 16 or 16.75 ug/ml (Figures 5, 6). 
KBr extract from tonsil cells continued to inhibit alternative pathway 
lysis by 65% while KBr extract fran Raji cells inhibited lysis by 10%. 
Qptimal COnditions for Inhibition of Lysis of EAC43 
In order to maximize the sensitivity for inhibition of alter­
native pathway lysis by KBr extracts, the effects of variations in 
time, temperature, pH and ionic strength during incubation of KBr ex­
tract from Raji cells with EAC43 were studied. 10-80 ug of extract 
was incubated for 0-90 minutes with EAC43. Fbllowing the preincuba­
tion, 3.6 ng/ml of factor B and 400 ng/ml of factor D was added and 
lysis due to alternative pathway detected as described in Materials 
and Methods. KBr extract from Raji cells produced a time dependent 
inhibition of the lysis of EAC43 by factors B, D, and C5-9 as shown in 
Figure 7. No appreciable changes in inhibition were seen after a 
preincubation with EAC43 of 60 minutes. At the two highest concen­
trations of extract, inhibition of subsequent lysis was seen with 0 
and 15 minutes of preincubation. 
Temperature dependence of inhibition of alternative pathway lysis 
was also tested as shown in Table 2. 10-80 ug of KBr extract fran 
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Figure 7. Time dependent influence of KBr extract from Raji cells 
on lysis of �43bBb. Concentrations of KBr extract ranging from 
10-80 ug/ml were incubated for varying interals at 37°C with �43 
before addition of 3.6 ng/ml of factor B and 400 ng/ml of factor D. 
11--11 10 ugjml. D-O 20 ugjml. ______. 40 ug/ml. 
o--o 80 ug/ml. 
Cll) 
0 
Cll) 
0 
� 
0 
N 
N 
0 0 
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TABLE 2 
INFWENCE OF TEMPERATURE CN INHIBITICN OF ALTERNATIVE 
PATHWAY LYSIS BY KBR EXTRJ\CT FROM RAJI CELIS 
Temperature 10 
30 c 0* 
0 c 47 
20 
25 
25 
% Inhibition 
Extract ug/ml 
40 
60 
24 
80 
44 
38 
*%of inhibition seen at 37°C with·identica1 concentrations of 
extract. EAC43 were incubated with indicated concentrations 
KBr extract at 0, 30 or 37°C for 1 hour prior to addition of 
2.5 ng/ml of factor B and 400 ng/ml of factor D. Inhibition 
at 37 C given by Z' units was 1.8, 1.25, 0.82 and 0.63 for 
concentrations of 80, 40, 20, and 10 ugjml, respectively. 
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Raji cells was preincubated with EAC43 for 1 hour at 37 c, at 30°C or 
at 0°C prior to addition of 2.5 ng/ml of factor B and 400 ng/ml of 
factor D. Residual alternative pathway lysis was detected exactly as 
described in Materials and Methods. 32-33% of maximal inhibition seen 
at 37°C was retained with preincubation at 30°C or at 0°C when all 
concentrations of extract tested were averaged. For nearly every con­
centration of extract tested, preincubation at 37°C was superior and 
therefore used for all subsequent experiments. 
Effects of varying ionic strengths on alternative pathway inhibi­
tion were tested in the following manner. Ionic strength was varied 
using appropriate amounts of GVB++ and 5% dextrose in water 
(D5W++) to generate the desired ionic strength. 8-128 ug of KBr 
extract from Raji cells in buffers with relative salt concentrations 
corresponding to either 0.15 M, 0.075 M or 0.0375 M saline were incu­
bated with �43. After incubation with the extract, 1.2 ng/ml of 
factor B and 400 ng/ml of factor D in buffers which restored the rela­
tive salt concentration of the cell suspension to 0.075 M saline were 
added and subsequent lysis due to the alternative pathway determined 
as described in the Materials and Methods. As shown in Figure 8, 
varying the ionic strength during preincubation between EAC43 and KBr 
extract from Raji cells did not have a consistent effect on.the amount 
of inhibition at all concentrations of extract tested, although an 
relative salt concentration of 0.075 M or 0.0375 M appeared to be 
somewhat superior to isotonicity. 
Finally, the effect of pH during the preincubation between EAC43 
and extract was examined. DGVB++ was adjusted to pH 6.0 or to pH 
so 
Figure 8. Effect of ionic strength on capacit y of KBr extract from 
Raji cells to inhibit lysis of EAC43bBb. Concentrations of KBr 
extract ranging from 8-128 ug/ml were incub ated for 1 hour at 37°C 
in three diff erent ionic strength buff ers with EAC43 before addi­
tion of 1.2 ng/ml of factor B and 400 ng/ml of factor D. Reaction 
mixtures were all adjusted to 0.075 M relative salt concentration 
when factors B and D were added. 
� 0.15 M. EZa 0.075 M. D 0.0375 M. 
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8.0 with 1 N NaOH or 1 N hydrochloric acid (HCl) for use or used at 
its usual pH of 7.3. 8-128 ug of KBr extract fran Raji cells were 
tested in IX>VB++ at either pH 6.0 or 7.3 • After preincubation with 
�43, 1.2 ng/ml of factor B and 400 ng/ml of factor D was added in pH 
8.0 or 7.3 buffer which returned the pH to 7.3-7.4 during generation 
of the alternative pathway convertase. Residual hemolysis due to the 
alternative pathway was determined as described in the Materials and 
Methods and shown in Figure 9. No consistent differences in subse­
quent lysis of FAC43 was seen when pretreatment by KBr extract was 
performed at pH 6.0 or at pH 7 .4. All subsequent experiments were 
performed with an relative salt concentration corresponding to 0.075 M 
saline at pH 7.4 for 1 hour at 37°C. 
Variability among Raji Cell Lines for Inhibition of Alternative 
Pathway Lysis 
In early experiments, two separate Raji cell lines, one obtained 
fran Dr. Chen (Raji CN), and the original A'ICC line obtained fran Dr. 
Daniel Conrad at the Medical College of Virginia (Raji DC) were tested 
for their ability to inhibit alternative pathway lysis and found to be 
positive.- Raji CN was kept in continuous passage for over 1 year 
while retaining the ability to inhibit the alternative pathway. KBr 
extracts were made at approximately one Jronth intervals during this 
time period and were consistently positive for inhibition of alter­
native pathway lysis. Raji DC was also kept in continuous passage the 
following year and retained the ability to inhibit the alternative 
pathway for 7 Jronths. Again, KBr extracts were made from this cell 
line at approximately one Jronth intervals and were consistently pos-
Figure 9. Effect of pH on capacity of KBr extract from Raji cell s 
to inhibit lysis of EAC43bBb.  Concentrations of KBr extract rang­
ing from 8-128 ug/ml were incubated for 1 hour at 37°C at pH 7.3 or 
6.0 with FJ\C43 bef ore addition of 1.2 ng/ml of factor B and 400 
ng/ml of factor D. Factors B and D were diluted in appropriate 
buffers which returned the pH to 7 .4. o---o pH 7 .4. 
� pH 6.0. 
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itive for inhibition of alternative pathway lysis. After the indi­
cated periods of time in culture, both cell lines on separate occa­
sions were found to be negative for inhibition of alternative pathway 
lysis. One of the cell lines, Raji CN, continued to be negative for 
at least two separate membrane preparations one month apart. Aliquots 
of one cell line, Raji OC, 1\tlich was frozen at -70°C were thawed, ex­
panded and used to reestablish a positive cell line. Because of the 
·apparent variation among Raji cells, three other Raji cell lines were 
subsequently obtained, expanded and tested for inhibition of the al­
ternative pathway. One line was obtained fran Dr. T. Mohanakumar 
(Raji Kumar) while another line was obtained fro m  Dr. M. Strachan, 
(Raji MS), both at the Medical College of Virginia. An additional 
Raji cell line was purchased fro m the American Type CUlture Collection 
(Raji AleC). 1-2 x 109 cells from all three sources plus the orig­
inal two lines (CN and OC) were used for membrane isolation and KBr 
extraction. Raji CN old and Raji OC old were the original cell lines 
used in initial observations of alternative pathway inhibition and 
were used in all other reported experiments. Raji CN new and Raji OC 
new were passages fran the original cell line which no longer inhib­
ited the alternative pathway. In Table 3 the amounts of KBr extract 
from various Raji lines and their ability to inhibit alternative path­
way lysis is shown. As extracts became available, the various cell 
lines were tested in five separate assays for inhibition of the alter­
native pathway and values given are all adjusted for a protein concen-
tration of 1 mg/ml. 
Cell 
Raji 
Raji 
Raji 
Raji 
Raji 
Raji 
Raji 
TABLE 3 
VARIABILITY IN RAJ! LINES FOR INHIBITION OF 
ALTERNATIVE PATHWAY LYSIS 
Line Inhibition (Z' per mg protein) 
CN old 5 •. 36 
CN new .07 
ATCC .00 
Kumar .20 
MS 
• 
10 
DC old 6.10 
DC new • 13 
Extracts were tested in five hemolytic assays for 
inhibition of lysis of EAC43bBb. All values are adjusted 
for an extract concentration of 1 mg/ml. 
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Subculture of Raji DC by Dilution 
Although the Raji cell lines established through dilution as de­
scribed in the Materials and Methods, were certainly not all derived 
from single·cell precursors, they were used to investigate the vari­
ability of inhibition of the alternative pathway by Raji cell lines. 
They were particularly useful in such studies, since their "diver­
gence" fran a ·single source occurred at a known time point, rather 
than anytime foll<=Ming the original derivation of the Raji cell line 
several years ago. Of the 20 cell lines established through dilution, 
three lines, R 1, R 10 and R 18 were selected at random and cultured 
in 1-2 liter spinner flasks. 1-2 X 109 cells from each cell line 
were used for membrane isolation and KBr extraction. Cell line R ·10 
produced a dose dependent inhibition of alternative pathway lysis 
(Figure 10). At 192 ug/ml R 10 caused a 54% inhibition of lysis, 
whereas in other experiments R 18 and R 1 showed no inhibition at 
similar concentrations. This result, along with the variability seen 
in cell lines obtained from a number of sources, suggests strongly 
that all Raji cell lines do not possess a membrane component which 
inhibits alternative pathway lysis. 
PMSF Sensitivity of Inhibition by KBr Extract from Raji and Tonsil 
Cells 
Tb test whether a serine protease was involved in inhibition of 
the alternative pathway by KBr extracts from either Raji or tonsil 
cells, phenylmethylsulfonylfluoride (PMSF) was added to the extracts 
and their residual ability to inhibit the alternative pathway assessed 
in two separate experiments. In the first, 0.5 ml of KBr extract from 
Figure 10. Influence of KBr extract from Raji cell subline RlO on 
lysis of EAC43bBb. Concentrations of KBr extract ranging from 
12-192 ug/ml were incubated for 1 hour at 37°C with EAC43 before 
addition of 197 ng/ml of factor B and 400 ng/ml of factor D. 
o--o RlO. 
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Raji cells (15-120 ug/ml) was treated either with 1 mM PMSF in isopro­
paml or isopropanol alone. EAC43 were added for 1 hour at 37°C, 
after which 197 ng/ml of factor B and 400 ng/ml of factor D were 
added. Isoproponal alone had no effect on subsequent lysis with fac­
tors B and D and C' EDTA. Alternative pathway lysis was determin&:l as 
described in the Materials and Hethods. As seen in Figure lla, no 
loss of inhibition of the alternative pathway was seen when KBr ex­
tract was treated with PMSF; in fact, an increase of about 5-30% at 
extract concentrations of 30, 60 and 120 ug was observed. In another 
experiment, 4. 5 to 36 ug of KBr extract from tonsil cells were treated 
with isopropanol or PMSF as described.above and incubated with EAC43 
for 1 hour at 37°C prior to addition of 197 ng/ml of factor B and 400 
ng/ml of factor D. In this case, extract treated with isopropanol 
alone had more activity than extract treated with PMSF in isopropanol 
(Figure llb). Some preservation of activity is seen with KBr extracts 
fran both cells treated with PMSF. 
These two observations prompted use of 1 mM PMSF throughout the 
entire membrane isolation procedure of a cell line, Raji NI'CC, which 
had failed earlier to inhibit alternative pathway lysis. A KBr ex­
tract fran this cell line isolated in the presence of 1 mM PMSF did 
oot inhibit the alternative pathway as sh<:Mn in Figure 12, though in 
the 5ame experiment a KBr extract from tonsil cells did inhibit lys­
is. No serine protease appears to be involved in the inability of 
this Raji cell line to inhibit the alternative pathway. 
Sensitivity of Alternative Pathway Inhibition to Proteolysis 
In order to characterize the nature of the factor(s) resulting in 
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Figure lla. Influence of 1 rrM PMSF on capacity of KBr extract from 
Raji cells to inhibit lysis of �43bBb. Concentrations of KBr 
extract ranging from 15-120 ug/ml wer e incubated as de scribed for 
Figure 10 with �43 prior to addition of 197 ng/ml of factor B and 
400 ng/ml of factor D. 0--0 isopropanol. -----. isopropanol 
with 1 rrM PMSF. 
llb. Infl uence of 1 rrM PMSF on capacity of KBr extract from tonsil 
cells to inhibit lysis of �43bBb. Concentrations of KBr extract 
ranging from 45-360 ug/ml were incubated as de scribed for Figure 10 
with �43 prior to addition of 197 ng/ml of factor B and 400 ng/ml 
of factor D. o--o isopropanol. ...___. isopropanol with 1 rrM 
PMSF. 
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Figure 12. Capacity of KBr extract from Raji A'J.'Cl: prepared in the 
presence of 1 mM PMSF to inhibit lysis of EAC43bBb. Concentrations 
of KBr extract from Raji A'J.'Cl: ranging from 14-225 ug/ml or KBr 
extract from tonsil cells ranging from 4.5-36 ug/ml were incubated 
as described for Figure 10 with EAC43 prior to addition of 47 ng/ml 
of factor B and 400 ng/ml of factor D. ._-. KBr extract from 
Raji cells. o----o KBr extract from tonsil cells. 
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inhibition of alternative pathway lysis by KBr extract from Raji 
cells, KBr extract was treated with three sources of proteases and 
tested for inhibition of alternative pathway lysis. Three concentra­
tions of trypsin (3.3 ug/ml, 33 ug/ml and 333 ug/ml) were used to 
treat KBr extract from Raji cells for 30 minutes at 37°C foll�ed by a 
four fold excess of soybean trypsin inhibitor prior to addition to 
�43. Control tubes containing KBr extract with the highest concen­
tration of SBTI as well as KBr extract alone were also included; no 
effect of SBTI alone on subsequent lysis was observed. As sho\.m in 
Figure 13, increasing amo unts of trypsin had no consistent effect on 
inhibition by KBr extract from Raji cells ranging from concentrations 
of 16-256 ug/ml. This observation was somewhat surprising, in view of 
the trypsin susceptibility of the C3b receptor on a number of cell 
types (28, 29). 
Another approach to this question utilized Sepharose Cl-4B which 
had either pronase or protease covalently attached using cyanogen bro­
mide as described in the Materials and Methods. 400 ug of KBr extract 
fran Raji cells was incubated at 37°C for 1 hour with 0.2 ml of anti­
HSA-Sepharose, pronase-Sepharose or protease-Sepharose. Both enzyme­
Sepharose conjugates had 1 mg/ml of enzyme attached. Supernates were 
removed, filtered over glass wool and tested for their ability to in­
hibit alternative pathway lysis. Fbllowing a 1 hour inucbation with 
�43, 1 ug/ml of factor B and 400 ng/ml of factor D was added for de­
tection of lysis as described in Materials and Methods. No loss of 
inhibition was seen with either enzyme (Figure 14). The covalently 
attached enzymes completely destroyed the hemolytic activity of 20 ug 
67 
Figure 13. Effect of trypsin treatment on capacity of KBr extract 
from Raji ce lls to inhibit lysis of EAC43bBb. 0.05 ml of KBr 
extract at 1.3 mg/ml was incubated with concentrations of trypsin 
ranging from 0 to 333 ug/ml for 30 minutes at 37°C. Subsequently, 
a four fold excess of soybean trypsin inhibitor was added and ex­
tracts tested for inhibition of alte rnative p athway lysis. COncen­
trations of KBr extract ranging from 16-256 ug/ml were incubated as 
described for Figure 10 with EAC43 prior to addition of 39.8 ng/ml 
of factor B and 400 ng/ml of factor D. 
_______. 256 ug/ml. o---o 128 ug/ml. Q--0 64 ug/ml. 
� 32 ug/ml. ........__..... 16 ugjml. 
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of factor B in a 1 hour in:::ubation at 37 C. 
MOlecular Weight Determinations 
71 
KBr extract from Raji cells (0.6 ml) was analyzed by gel filtra­
tion on Sephacryl 300 in 2 M KBr with 0.01 M HEPES. Fractions were 
dialyzed and tested for their ability to inhibit the alternative path­
way. Peak inhibition was observed shortly after the void volume of 
the column corresponding to an apparent I!Olecular weight of 470,000 
daltons (Figure 15). KBr extract from tonsil cells (0.6 ml) in 2M 
KBr was analyzed in a similar fashico and is shown in the same fig­
ure. Peak activity eluted corresponding to an .apparent I!Olecular 
weight of 270,000 daltons. Extracts of tonsil cell membranes with 1% 
NP-40 were also analyzed by gel filtration using Sephacryl 200 in the 
presence of 0.1% NP-40. Fractions were analyzed for protein by Lowry 
determinations and on two occasions for inhibitico of the alternative 
pathway. 'lWo separate peaks of activity were detected in both in­
stances, corresonding to apparent·molecular weights of 155,000 and 
52,000 daltons. The elution profile of this column is shown in Figure 
16. The d iscrepancy in molecular weight of inhibition of alternative 
pathway lysis by tonsil cells extracted in these two manners suggests 
that in 2 M KBr there remains some aggregation of membrane material. 
MOlecular weights of inhibitor(s) of the alternative pathway in 2M 
KBr of either KBr extract from Raji or tonsil cells are probably spur­
iously high. 
Absence of Cross-Reactivity with C3b Control Proteins 
Since both Raji cells and B lymphocytes have been rePorted to 
synthesize factor I in the presence of factor H (41), KBr extracts 
Figure 15. Sephacryl 8-300 gel filtration of KBr extracts from 
Raji and tonsil cells. The values for Kav derived from elution 
volume are plotted against standards of known molecular weight and 
the elution positions of each shown. The values for Kav derived 
from peak elution of Z' values reflecting inhibition of alternative 
pathway lysis are also shown. Standards are chymotrypsinogen, 
ovalbumin, and IgG. 
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Figure 16. Sephacryl s-200 gel filtration of 1% NP-40 extract from 
tonsil cells. Cblumn fractions were tested on two separate occa­
sions for inhibition of alternative pathway lysis. They were also 
tested for protein. Peak elution of molecular weight standards are 
shown. Standards are identical to those used in Figure 15 with the 
addition of ribonuclease. 
� Z' values from assay 1. 
� Z' values from assay 2. 
� ug/ml protein. 
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fran both Raji and tonsil cells were adsorbed with Sepharose-bound 
antibodies to factor H, factor I or HSA to determine if inhibition was 
due to their content of factors I or H. Adsorption by Sepharose-bound 
anti-factor H did not remove 68% of all alternative pathway inhibition 
due to KBr extracts from Raji cells as shown in Table 4 though the 
colurm had a capacity of 1. 47 ug of purified factor H. 'Ihis amount of 
factor H had a Z' value of approximately 3. After adsorption with 
anti-factor I, KBr extract from Raji cells retained 70% of its ability 
to inhibit the alternative pathway, though an equivalent amount of im­
munoadsorbent was capable of removing 0.588 ug of partially purified 
factor I. 'Ihis amount of factor I yielded a Z' value of approximately 
1. These experiments indicate little if any immunologic cross­
reactivity between KBr extract from Raji cells and factors I and H. 
An identical experiment utilizing KBr extracts from tonsil cells was 
performed using all three antibodies. Adsorption with any of these 
immunoadsorbents failed to remove inhibition of the alternative path­
way due to KBr extract as shown in Table 5. The apparent two fold de­
crease in activity per mg of protein seen with anti-HSA reflects small 
variation in inhibition which is multiplied in the calculations. 
Influence of a Serum Factor(s) on Inhibition of Alternative Pathway 
Lysis due to KBr Extract from Raji and 'Ibnsil Cells 
In the course of testing monoclonal culture supernates for their 
ability to remove inhibition of the alternative pathway by KBr ex­
tract?, calf serum was found to contain a factor(s) which completely 
blocked the ability of KBr extract from Raji cells to inhibit the 
lysis of EAC43bBb. Addition of 0.5% FCS and 0.5% NBCS (which had been 
TABLE 4 
IMMUNOADSORPTION OF KBR EXTRACT FROM RAJ! CELLS WITH 
AFFINITY ADSORBENTS FOR HSA, FACTOR H AND FACTOR I. 
Experiment Immunoadsorbent Activity/mg protein 
Anti -HSA 
Anti -factor H* 
2 Anti -HSA 
Anti -factor I** 
*Column adsorbed 1.47 ug of factor H. 
**Adsorbent adsorbed 0.59 ug of factor I. 
118.5 Z' 
80.5 Z' 
44.6 Z' 
35.1 Z' 
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TABLE 5 
IMMUNOADSORPTION OF KBR EXTRACT FROM TONSIL CELLS WITH 
AFFINITY ADSORBENTS FOR HSA, FACTOR H AND FACTOR I 
Il11llunoadsorbent Activity/mg protein 
Anti-HSA 
Anti-factor H* 
Anti -factor I** 
*Adsorbent adsorbed 5.1 ug of factor H. 
**Adsorbent adsorbed 9.8 ug of factor I. 
524.3 Z' 
858.9 Z' 
1054.0 Z' 
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incubated at 56°C for 30 minutes prior to use in tissue culture to 
eliminate oanplement activity) to KBr extract fran Raji cells com­
pletely abolished its effect on the alternative pathway (Figure 17). 
Similarly, addition of 0.5% FCS and 0.5% NBCS to KBr extract from ton­
sil cells reduced inhibition of the alternative pathway by 50% at 136· 
ug/ml of extract, by 90% at 68 ug/ml of extract and completely abol­
ished inhibition due to 17 and 34 ug of extract (Figure 18). A par­
tial characterization of this factor was undertaken. First, a similar 
effect can be denonstrated using human serum as well as calf serum. 
Human serum was first incubated at 60°C for 30 minutes to eliminate 
inhibition of the alternative pathway due to factor H in serum. 
Addition of 1% normal human serum caused a reduction in inhibition due 
to KBr extract from Raji cells as denonstrated in Figure 19. Inhib­
ition of the alternative pathway was eliminated at extract concentra-· 
tions of 3. 75-15 ug/ml and was reduced by 70% at concentrations of 30 
and 60 ug/ml. In additional experiments, the effects of dialysis, 
further heat-treatment of calf serum or treatment of calf serum with 
lmM PMSF on elimination of inhibition due to KBr extract fran Raji 
cells were examined. As seen in Tables 6 and 7, neither dialysis nor 
treatment of calf serum with 1 mM PMSF destroyed the ability calf 
serum to block inhibition of alternative pathway lysis by KBr extract 
fran Raji cells. Only additional heating for 1 hour at 60°C reduced 
the effects of serum on inhibition of alternative pathway lysis due to 
KBr extract fran Raji cells. 
Relationship of KBr Extract from Raji or Tbnsil Cells to gp205 
Since gp205 is known to inhibit alternative pathway lysis by 
80 
Figure 17, Infl uence of calf serum on capacity of KBr extract from 
Raji cells to inhibit lysis of FAC43bBb. Concentrations of KBr ex­
tract ranging from 7 . S-UO ug/ml were iocubated with FAC43 in the 
presence or absence of 0.5% FCS and 0.5% NBCS as described in Fig­
ure 10 prior to addit ion of 197 .• 5 ng/ml of factor B and 400 ng/ml 
of factor D. o---o IGVB++. .--e rx;w++ with FCS and NBCS. 
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Figure 18. Infl uence of calf serum en capacity of KBr extract from 
tonsil cells to inhibit lysis of EIIC43bBb. Concentrations of KBr 
extract ranging from 17-136 ug/ml were incubated with EIIC43 in the 
presence or· absence of 0.5% FCS and 0.5% NBCS as described for Fig­
ure 10 prior to additicn of 20 ng/ml of factor B and 400 ng/ml of 
factor D. o--o JXNB++ • .--. IXNB++ with 0.5% FCS and 0.5% 
NBCS . 
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Figure 19. Infl uence of human sen.nn on capacity of KBr extract 
from Raji cells to inhibit lysis of EAC43bBb. Concentrations of 
KBr extract ranging from 3. 75-60 ug/ml were incubated with EAC43 in 
the presence or absence of 1% normal human serum as.described in 
Figure 10 prior to addition of 20 ng/ml of Factor B and 400 ng/ml 
of factor D. 0-:--0 J:GVB++. e-----e J:GVB++ with 1% normal human 
serum. 
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TABLE 6 
CHARACTERISTICS OF CALF SERUM INHIB ITOR 
Inhibition (Z') 
Extract ug/ml 
Serum Treatment 120 60 30 15 
No serum 1.58 1.54 1.00 • 73 
None .07 .09 .05 .00 
Dialysis .00 .00 .00 .00 
60°C 1 hr 1.41 .52 • 15 .00 
EAC43 were incubated with KBr extract from Raji cells in 
DGVB++ in the presence or absence of .5% fetal calf 
serum and .5% newborn calf serum. After 1 hour at 
37°C, factor B at 197 ng/ml and factor D at 400 ng/ml 
were added. 
86 
TABLE 7 
TREATMENT OF CALF SERUM WITH PMSF 
Inhibition (Z') 
Extract ug/ml 
Serum treatment 120 60 30 
No serum 1.00 .76 .40 
No serum-PMSF 1.49 1.03 .51 
None .00 .00 .00 
PMSF .00 .00 
• 15 
EAC43 were incubated with KBr extract from Raji cells in 
DGVB++ in the presence or absence of .5% FCS and .5% NBCS 
which was untreated or treated with 1 mM PMSF. After 1 
hour at 37°C, factor B at 197 ng/ml and factor D at 400 
ng/ml were added. 
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accelerating decay of factor B from EAC3bBb, the effect of antibody to 
gp205 on the activity of KBr extracts fran both Raji and tonsil cells 
was of interest. Affinity-purified anti-gp205 (Fab')2, a gift of 
Dr. Douglas Fearon, was used to block inhibition of alternative path­
way lysis by KBr extract from both Raji and tonsil cells (Figure 20) • 
Amounts of antibody as lCM as 8 ng/ml ocmpletely removed inhibition of 
the alternative pathway due to KBr extract from tonsil cells whereas 
only about 40% of inhibtion due to KBr extract fran Raji cells was re­
noved by similar arrounts of antibody. In the same experiment in data 
not sh<:Mn, concentrations of anti-gp205 (Fab')2 as much as forty-
fold higher still resulted in loss of only 40% of inhibition due to 
KBr extract from Raji cells. Affinity purified anti-gp205 by itself 
had no effect on inhibition of alternative pathway lysis due to factor 
H . 
The ability of another source of anti-gp205, a monoclonal anti­
body to the C3 receptor, kindly provided by Drs. Gerdes and Stein, was 
also tested for its ability to rembve inhibition of the alternative 
pathway due to KBr extracts. 'lb eliminate effects of calf serum which 
was present in the supernate of the oonoclonal culture both KBr ex­
tracts were preincubated with a source of antibody for 30 minutes, 
centrifuged at 48,000 x G for 1 hour and resuspended in _VBS. M:>use 
oono:::lonal antibody to IgE obtained fran Dr. Daniel Conrad or anti-c3 
receptor were tested for their ability to block inhibition due to KBr 
extracts (Figure 21). At the single dilution of monoclonal supernate 
used, anti--<::3 receptor removed inhibition of the alternative pathway 
due to KBr extract fran tonsil cells, whereas it had no 
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Figure 20. Influence of (Fab')2 fraction of rabbit antibody to 
gp205 on capacity of KBr extracts from Raji and tonsil cells to 
inhibit lysis of EAC43bBb. · Extracts or factor H were incubated 
with EAC43 in the presence of concentrations of anti-gp205 ranging 
from 0-16 ng/ml as described in Figure 10 prior to addition of 790 
ng/ml of factor B and 400 ng/ml of f actor D • ...--. KBr extract from 
Raji cells (887.5 ug/ml).D---0 KBr extract from tonsil cells (37.4 
ug/ml). o---o Factor H (262 ng/ml). 
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Figure 21. Influence of rronoclcnal anti-c3 receptor or anti-IgE on 
capacity of KBr extracts from Raji and tonsil cells to inhibit lys­
is of EAC43bBb. Monoclonal antibody was incubated with KBr ex­
tracts on ice for 30 minutes, centrifuged at 48,000 x G for 1 hour, 
and resuspended in VBS .  COncentrations o f  KB r  extract from Raji 
cells ranging from 14-ll2 ug/ml and tonsil cells ranging from 16-
128 ug/ml were incubated with EAC43 as described for Figure 10 
prior to addition of 790 ng/ml of factor B and 400 ng/ml of factor 
D. o--o KBr extract from Raji cells with anti-IgE • ...-. KBr 
extract from Raji cells with anti-c3 receptor. D---o KBr extract 
fran tonsil cells with anti-IgE • .__ KBr extract from tonsil 
cells with anti-c3 receptor. 
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effect on that inhibition seen in the presence of KBr extract from 
Raji cells. A control rroncx:lonal anti-IgE had oo effect on the abil­
ity of either KBr extract to inhibit the alternative pathway. The 
source of anti-c3 receptor used in Figure 21 was found to block imnune 
adherence of human erythrocytes and EAC43 (Figure 22). 
Influence of KBr Extracts on Alternative Pathway C3 Convertase 
KBr extract from Raji cells which inhibited alternative pathway 
lysis was tested for its ability to potentiate the decay of factor B 
from EAC43bBb. EAC43bBb were prepared using 781 ng/ml of factor B and 
400 ng/ml of factor D. Subsequently, either VBS in 0.01 M EDTA/GVB or 
KBr extract in 0.01 M EI:Ym/GVB was added to a pellet of EAC43bBb cells 
and the mixture incubated at 30°C. Residual herrolytic sites present 
oo the EAC43bBb after various time intervals up to 30 minutes were de­
termined and t 1/2 of the convertase in the presence of buffer or ex­
tract calculated. As can be seen in Table 8, 735 ug of KBr extract 
from Raji cells decreased the half-life of the convertase from 5.5 to 
2.3 minutes, a decrease of 41%. KBr extract from Raji cells also po­
tentiated factor B decay from properdin-stabilized EAC43bBbP in a dose 
dependent manner; however, KBr extracts from Daudi cell membranes did 
oot cause accelerated decay of EAC43bBb (Daniel Conrad, personal 
cx::mnunication) • 
In parallel experiments, KBr extract from tonsil cells was also 
tested for its influence on the alternative pathway convertase (Table 
9). EAC43bBb were prepared with 494 ng/ml of factor B and 400 ng/ml 
of factor D. 29 ug of KBr extract from tonsil cells was found to po­
tentiate factor B decay from EAC43bBb by 68% causing a reduction in 
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Figure 22. Effect of !lPl'loclonal antibody on receptor on human eryth­
rocytes f or EAC43. 0.025 ul of monoclonal antibody diluted 1:10 was 
incubated at 4 C with 0.025 ul of human erythrocytes at 5 x 1071m1 
foe 1 hour prior to additi on of 0.025 ul of EAC43 at 4 x 107;m1. 
ReM 1. Anti-c3 receptor. RaN 2. Anti-IgE. RaN 3. �++. 
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Fraction 
VBS 
Raji 
TABLE 8 
INFLUENCE OF KBR EXTRACT FROM RAJ! CELLS 
ON DECAY OF EAC43bBb 
Extract ug/m1 
735 
t 1/2 (minutes) 
5.5 
2.3 
EAC43 were incubated with 781 ng/m1 of factor B and 400 
ng/m1 of factor D for 10 minutes at 30°C. 
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TABLE 9 
I NFLUENCE OF KBR EXTRACT FROM TONSIL CELLS 
ON DECAY OF EAC43bBb 
Fraction Extract ug/ml t l/2 (minutes) 
VBS 4.0 
Tonsil 29 1.7 
EAC43 were incubated with 494 n g/ml of factor B and 400 
ng/ml of factor D for 10 minutes at 30°C. 
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half-life of the convertase from 4 minutes to 1.7 minutes. In other 
experiments, the reduction in half-life of alternative pathway con­
vertase due to KBr extract from tonsil cells was shown to be dose 
dependent. 
Tb determine whether the loss of hemolytic activity of EAC43bBb 
was in fact due to physical dissociation of factor B from the conver­
tase, the follao�ing experiment using radiolabeled factor B on zymosan 
was performed. Zymosan bearing the alternative pathway convertase 
generated as described in the Materials and Methods (ZC3bBbP) was pel­
leted and 0. 6 mg was resuspended in 0. OS m1 of VBS alone or VBS con­
taining 65 ug of KBr extract from Raji cells or 90 ng of factor H. 
Replicate samples were prepared for VBS and KBr extract from Raji 
cells. ZynPsan suspensions were then incubated at 30°C for 15 mi­
nutes. Following this incubation, all tubes were centifuged at 850 x 
G for 5 minutes and zymosan washed 2 times with r:x:;vB++. Radioactivity 
remaining bound to zymosan particles was then counted and % loss of 
125r for each tube determined. Decay in VBS alone was 19.2% and 
19%, while factor H caused a decay of 52�. Decay in VBS containing 65 
ug of KBr extract from Raji cells was 29% and 27 .5%. Results similar 
to these were found in two other experiments. Tbgether with the hemo­
lytic decay of EAC43bBb, these experiments provide support for the no­
tion that inhibition of lysis due to KBr extract from Raji cells is 
due in part to actual loss of factor B from the alternative pathway 
convertase, rather than an "inactivation" of its function while it re­
mains present in the convertase. 
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Influence of Fluid-Phase C3, C3b and C3bi on Decay of EAC43bBb in the 
Presence of KBr Extract from Raji and Tbnsil Cells 
Previous experiments (88) have shown that fluid-phase C3 and C3b 
blocked binding of factor H to EAC43bBb. In order to detect inter­
action between C3 or its cleavage products and KBr extracts, decay of 
factor B from EAC43bBb was determined in the presence of fluid-phase 
C3, C3b and C3bi. It was postulated that specific ligand (i.e. C3, 
C3b, or C3bi) would interfere with the ability of KBr extract from 
either cell type to cause accelerated decay of factor B from 
EAC43bBb. For testing the effect of C3, EAC43bBb were pre pared with 
175 ng/rnl of factor B and 400 ng/rnl of factor D and resuspended in .vss 
in 0.01 M ED�/GVB alone or with factor H, KBr extract from Raji 
cells, or KBr extract from tonsil cells. One set of tubes for each 
test material contained 48-780 ug/rnl of fluid-phase C3. Hemolysis at 
0 or 9 minutes was determined as described in Materials and r-�ethods. 
As shown in Table 10, the t 1/2 of EAC43bBb in VBS alone was 7.2 
minutes and fell to 3.0, 3.0, or 2.4 minutes in the presence of KBr 
extract from Raji cells, KBr extract from tonsil cells or factor H, 
respectively. C3 had no dose dependent effect on the increased decay 
of EAC43bBb due to KBr extract from e ither Raji or tonsil cells, but 
it did reverse the increased decay of EAC43bBb due to factor H in a 
dose dependent manner. A decrease of 70% in half-life of the conver­
tase in the presence of factor H was reduced to only 30% with concen­
trations of C3 of 390 ug/rnl or greater. 
C3b was also tested in similar experiments (Table ll) • In pre­
liminary experiments, fluid-phase C3b was shown to inhibit accelerated 
TABLE 10 
INFLUENCE OF FLUID-PHASE C3 ON DECAY OF EAC43bBb 
DUE TO KBR EXTRACT FROM RAJ! OR TONSIL CELLS 
t 1/2 (minutes) 
Amount of C3 ug/ml 
Fraction 780 390 195 98 48 0 
VBS NT NT NT NT NT 7.2 
Raji 2.7 2.7 2.6 NT NT 3.0 
Tonsil 3.7 3.8 3.6 NT NT 3.0 
Factor H 5.0 4.9 3.0 3.0 2.7 2.4 
NT = not tested. Value given is t l/2 of EAC43bBb in minutes. 
EAC43 were incubated with 175 ng/ml of factor B and 400 
ng/ml of factor D for 10 minutes at 30°C. · KBr extract from 
Raji ce l ls was used at 201 ug/ml. KBr extract from tonsil 
cells was used at 156 ug/ml. Factor H was used at 524 ng/ml. 
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TABLE 11 
INFLUENCE OF FLUID-PHASE C3b ON DECAY OF EAC43bBb 
DUE TO KBR EXTRACTS FROM RAJI AND TONSIL CELLS 
Fraction 
VBS 
Raji 
Tonsil 
98 
NT 
8.0 
5.5 
t 1/2 (minutes) 
Amount of C3b ug/ml 
49 
NT 
8.0 
4.0 
24 
NT 
8.0 
3.8 
12 
NT 
a. 1 
3.3 
0 
20.0 
6.9 
2.5 
NT= not tested. Values given are t 1/2 of EAC43bBb in 
minutes. EAC43 were incubated with 263. ng/ml of 
factor B and 400 ng/ml of factor D. KBr extract from Raji 
cells was used at 500 ug/ml. KBr extract from tonsil cells 
was used at 187 ug/ml. 
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decay of EAC43bBb due to factor H. EAC43bBb were prepared with 263 
ng/ml of factor B and 400 ng/ml of factor D. The factor B preparation 
used for this experiment apparently contained anounts of properdin 
which stabilized the alternative pathway convertase so that a longer 
half-life was observed in this case and in several other experiments. 
Decay of factor B from EAC43bBb was determined in test materials pre­
pared in an identical manner to that used for C3 described above. One 
set of tubes with each KBr extract contained C3b from 12-98 ug/ml. 
After 0 or 8 minute� of decay at 30°C, residual EAC43bBb sites were 
detected using rat serum as described in Materials and Methods. In 
this experiment, the reduction in half-life from 20 minutes to 2. 5 
minutes (87%) by KBr extract from tonsil cells was lowered to only 5.5 
minutes (62%) by 98 ug/ml of C3b. LcMer concentrations of C3b yielded 
intermediate values, approaching a half-life seen in the presence of 
KBr extract from tonsil cells. In contrast, the reduction in half­
life by KBr extract from Raji cells from 20 minutes to 6.9 minutes 
(65%) was changed to 8.0-8.1 minutes (60%) in the presence of 24-98 
ug/ml of C3b. Fluid-phase C3b did not have a dose dependent effect on 
decay due to KBr extract from Raji cells. Figure 23 shows another ex­
periment using only KBr extract from tonsil cells and presents another 
example of the effect of fluid-phase C3b (2.5-40 ug/ml) on accelerated 
decay of EAC43bBb due to KBr extract. EAC43bBb were prepared exactly 
as described above. After 0 or 8 minutes of decay at 30°C, residual 
EAC43bBb sites were detected using rat serum as described in the Ma­
terials and Methods. Accelerated decay of EAC43bBb in the presence of 
KBr extract from tonsil cells was again shown to be inhibited in a 
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Figure 23. Influence of fluid-phase C3b on capacit y of KBr extract 
from tonsil cells to accelerate decay of �43bBb. KBr extract 
(187 ug/ml) was incubated with �43bBb alone or in the presence of 
C3b fran 2.5-40 ug/ml. �43bBb were alro incubated in VBS-0.01 M 
ED'ffi/GVB with no KBr extract. �43bBb were prepared with 263 ng/ 
m1 of factor B and 400 ng/ml of factor D. 
• 0 ug/ml of C3b • 
" 2.5 ug/ml of C3b. 
... 5 ug/ml of C3b • 
b. 10 ug/ml of C3b. 
• 20 ug/ml of C3b • 
0 40 ug/ml of C3b. 
0 VBS-0.01 M ED'ffi/GVB. 
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dose-dependent manner by C3b. In the presence of KBr extract from 
tonsil cells and 40 ug/ml of C3b, half-life of the =nvertase was 3.2 
times that seen with KBr extract alone. 
Since C3bi is reported to be one of the fragments of C3 with 
which Raji cells interact, rather than C3b, decay of FAC43bBb in the 
presence of KBr extracts from Raji or tonsil cells and C3bi was of 
interest. FAC43bBb were prepared with 153 ng/ml of factor B and 400 
ng/ml of factor D. Decay of factor B in various test materials was 
performed' in an identical manner to that described above for C3. One 
set of tubes for each material contained 109-875 ug/ml of C3bi. Ac­
celerated decay of EAC43bBb due to KBr extract from Raji cells was not 
affected by soluble C3bi in a dose dependent manner (Table 12) • Decay 
due to KBr extract from Raji cells was actually faster by 3. 1 minutes 
with concentrations of C3bi of 109 ugjml. Decay due to KBr extract 
from tonsil cells was inhibited by all concentrations of C3bi tested, 
although this was not dose dependent. On the other hand, decay of 
EAC43bBb in the presece of factor H 1'/aS inhibited by fluid-phase 
C3bi. Factor H alone caused a reduction in half-life from 18.1 mi-
nutes in VBS to 3. 6 minutes (80%). In the presence of 875 ug of C3bi 
and factor H half-life was reduced to 5. 8 minutes (68%). Smaller a-
nounts of C3bi resulted in half-lives approaching that seen with fac­
tor H alone. Since this experiment utilized 8 to 9 times more C3bi 
than the previous experiments using C3b, the effect of C3bi on decay 
due to factor H could conceivably be due to snail amounts of C3b re­
maining in the preparation of C3bi. Although an intact a' chain of 
the C3bi preparation indicating incomplete cleavage of C3b to C3bi was 
not visible on sodium dodecyl sulfate preparative gel electrophoresis 
TABLE 12 
INFLUENCE OF FLUID-PHASE C3bi ON DECAY OF EAC43bBb 
DUE TO KB R EXT RACTS FROM RAJ! AND TONSIL CELLS 
t 1/2 (minutes) 
Amount of C3bi ug/ml 
Fraction 875 438 219 109 0 
VBS NT NT NT NT 18.1 
Raji 9.5 7.5 7.5 6.9 10.0 
Tons i1 5.0 4.2 4.6 4.6 3.0 
Factor H 5.8 5.2 4.9 4.0 3.6 
NT = not tested. Values given are t 1/2 of EAC43bBb in 
minutes. EAC43 were incubated with 153 ng/ml of 
factor B and 400 ng/ml of factor D. KBr extract from 
Raji cells was used at 151 ug/ml. KBr extract from 
tonsil cells was used at 94 ug/ml. Factor H was used at 
262 ng/ml. 
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(SDS-PAGE) analysis, the persistence of small amounts of C3b cannot be 
completely ruled out. Alternatively, C3bi may retain a binding site 
for factor Fi. 
Relationship of Alternative Pathway Inhibition due to KBr Extract from 
Raji and Tbnsil Cells with gp205 
Previously discussed experiments had shown that inhibition of al­
ternative pathway lysis by KBr extract from Raji cells could not be 
ccmpletely blocked by anti -gp205 (Fab') 2: whereas inhibition of 
lysis due to KBr extract from tonsil cells was blocked by anti-gp205. 
Since KBr extract from.both Raji and tonsil cells also accelerated de­
cay of factor B from EAC43bBb, anti-gp205 (Fab')2 were tested for 
their ability to block acceLerated decay due to either KBr extract 
(Table 13). EAC43bBb were prepared with 204 ng/ml of factor B and 400 
ng/ml of factor D. EAC43bBb were then resuspended in VBS with 0.01 M 
�/GVB alone or in the presence of KBr extracts or factor H. Decay 
for 0 or 9 minutes at 30°C was determined by the addition of rat serum 
as described in Materials and Methods for detection of residual 
EAC43bBb sites. Factor H, KBr extract from Raji cells, or KBr extract 
from tonsil cells were tested alone or in the presence of 0.63 ug or 5 
ug of (Fab')2 anti-gp205. Addition of 0.63 ug of anti-gp205 to KBr 
extract from tonsil cells increased the half-life of the convertase 
from 3.8 to 5.8 minutes. Addition of 5 ug of anti-gp205 to KBr ex­
tract from tonsil cells increased the half-life of the convertase to 
·7.6 minutes, which is similar to the value of in VBS of 8.8 minutes. 
· However, the same amounts of anti-gp205 did not cause an increase in 
the half-life of the convertase in the presence of KBr extract from 
TABLE 13 
INFLUENCE OF ANTI-GP 205 ON DECAY OF EAC43bBb 
DUE TO KBR EXTRACTS FROM RAJI OR TONSIL CELLS 
t 1/2 (minutes) 
Amount of Anti-gp205 
Fraction 5.0 ug 0.63 ug 0 ug 
VBS 9.2 NT 8.8 
Raji 4.0 4.4 5.2 
Tonsil 7.6 5;8 3.8 
Factor H 4.2 4.6 4.2 
NT = not tested. Values g iven are t l/2 of EAC43bBb in 
minutes. EAC43 were incubated with 204 ng/ml of 
factor B and 400 ng/ml of factor D. KBr extract from Raji 
cells was used at 202 ug/ml. KBr extract from tons il cells 
was used at 125 ug/ml. Factor H was used at 349 ng/ml. 
10 8 
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Raji cells, which by itself decreased t 1/2 to 5.2 minutes. In fact, 
both concentrations of antibody appeared to decrease the half-life 
even further. Finally, as a control for effects of anti -gp205 on 
Ei\C43bBb decay, the same am:mnts of anti-gp205 had no effect on the 
decrease in half-life due to factor H. 
COmparison of KBr EXtract from Tbnsil Cells with Factor H on 
Cell-Bound C3b 
Earlier work on factor H had shown a marked synergy with factor I 
on cleavage of cell-bound C3b. Amounts of inhibition observed in the 
presence of both factors I and H is about 5 times· that expected if in­
hibition were additive· in nature. KBr extract from Raji cells had 
been tested earlier for its ability to serve as a cofactor for factor 
I on cell-bound C3b and found not to synergize with factor I (Daniel 
Ccnrad, personal <XJII1llunication) • KBr extract from tonsil cells was 
also tested for its capacity to serve as a cofactor for factor I. 
FAC14°xy23 were prepared as described in the Materials and Methods 
with an amount of C3 resulting in about 50% lysis. Cells were incu­
bated with concentrations of factor I frOm 12.5 to 100 ng/ml alone or 
in the presence of 33 ng/ml of factor H or 2.3 ug/ml of KBr extract 
from tonsil cells. As can be seen in Figure 24, factor H alone re­
sulted in a Z' value of 0.439, but cl early synergized with very low 
arrounts of factor I which by itself caused little inhibition. KBr 
extract from tonsil cells alone resulted in a Z' value of 0.735 and 
had only an additive effect with identical amounts of factor I. Thus, 
KBr extract from tonsil cells, like KBr extract from Raji cells, does 
not act synergistically with factor I on cell-bound C3b to reduce he-
Figure 24. Influence of factor H or KBr extract from tonsil cells 
on activity of factor I. Concentrations of factor I ranging from 
12.5-100 ug/ml were incubated with EAC14°xy23 alone or in the 
presence of KBr extract from tonsil cells (2.3 ug/ml) or factor H 
(33 ng/ml). EAC14°xy23 were then incubated for 1 hour at 37°C 
with C5--c9. o--o factor I. D----0 factors I and H • .__. factor 
I and tonsil KBr extract. 
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mlysis. 
COmparison of KBr Extracts from Raji and Tbnsil Cells on Fluid-Phase 
C3b 
KBr extracts from both Raji and tonsil cells were tested for 
their ability to act as a cofactor for factor I in the cleavage of 
fluid phase C3b, since factor H has been shown to be an absolute 
requirement in this system (21). Figure 25 is an SD5-PAGE electro­
phoretic analysis of C3b incubated with factor H, factors I and H, KBr 
extract fran Raji cells, or KBr extract fran Raji cells and factor I. 
Track 1 shows the a and 6 chains of C3b incubated with factor H alone 
for 60 minutes. Tracks 2 and 3 demonstrate the results of factors I 
and H for 30 and 60 minutes, respectively, and show the expected 
cleavage of the a chain with the appearance of a new peak of 42,000 
daltons consistent with C3bi. KBr extract from Raji cells incubated 
with C3b alone for 60 minutes was without effect by itself as seen in 
Track 4. In the presence of factor I for 30 or 60 minutes in Tracks 5 
and 6, KBr extract fran Raji cells failed to serve as a cofactor for 
factor I. In contrast as shown in Figure 26, KBr extract from tonsil 
cells as well as factor H resulted in cleavage of the a chain of 
fluid-phase C3b. Sane cleavage of the a chain occurred in all cases 
as seen in Track 1 which sh<:MS the results of a 30 minute inucbation 
of C3b alone. Incubation of C3b with factors I, H or KBr extract from 
tonsil cells resulted in no additional cleavage of the a chain as il­
lustrated in Tracks 2, 4, and 5, respectively. Additional cleavage of 
the a chain as the result of the activity of factor H as a cofactor 
for factor I is seen in Track 3. Additional cleavage of the a chain 
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Figure 25. SDS-PAGE analysis of fluid-phase C3b. C3b was incu­
bated alone or with KBr extract fran Raji cells and/or C3b control 
proteins. All reaction mixtures contained C3b at 50 ug/ml in 0.04 
ml of VBS. In track 1, C3b was incubated for 60 minutes with fac­
tor H (1 ug/ml). In tracks 2 and 3, factor I (6.25 ug/ml) and fac­
tor H (1 ug/ml) were incubated with C3b for 30 and 60 minutes, re­
spectively. In track 4, KBr extract (738 ug/ml) was incubated with 
C3b alone for 60 minutes. In tracks 5 and 6, KBr extract (738 ug/ 
ml) and factor I (6.25 ug/ml) were incubated with C3b for 30 and 60 
minutes, respectively. After incubation, suramin sodium at 1 mg/ml 
was added; samples were dialyzed overnight versus 0.0625 M Tris-HCl 
and analyzed by SD5-PAGE on 10% acrylamide gels. 
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Figure 26. . SDS-PAGE analysis of fluid-phase C3b. C3b was incubat­
ed alone or with KBr extract from tonsil cells and/or C3b control 
proteins. Concentrations of C3b, factor I and factor H were iden­
tical to those described for Figure 25. KBr extract from tonsils 
cells was tested at 625 ug/ml. All incubations were for 30 minutes 
at 37°C and samples were handled exactly as described for Figure 
25. In Track 1, C3b was incubated alone. In Track 2, factor I was 
added. In Track 3, factors I and H were added. 
H was added. In Track 5, KBr extract was added. 
In Track 4, factor 
In Track 6, fac-
tor I and KBr extract were added. In Track 7, factor H and KBr ex­
tract were added. 
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by factor I in the presence of KBr extract from tonsil cells was also 
de!lonstrated in Track 6. The ability of KBr extract fran tonsil cells 
to serve as a a:>factor for factor I in cleavage of fluid-phase C3b is 
in contrast to its inability to serve as a a:>factor in the cleavage of 
cell-bound C3b as determined by inhibition of lysis. Factor H serves 
as a rofactor for factor I for cleavage of both fluid-phase and cell­
bound C3b. 
Influence of KBr Extract fran Raji and Tonsil Cells on the Classical 
Pathway 
The previous observation that KBr extract from Raji cells in­
hibited alternative pathway lysis prompted examination of its ability 
to influence the classical pathway. EAC4 were treated for 1 hour at 
37°C with 18.75-150 ug/ml of extract, after which treated and untreat­
ed EAC4 were used to quantitate arrounts of hemolytic Cl. In experi­
ment 1 of Table 14, KBr extract fran Raji cells shows a dose dependent 
inhibition of lysis due to C1 which by itself resulted in 92% lysis. 
To approach possible mechanisms for this inhibition, an experiment was 
performed in which an arrount of C1 resulting in 93% lysis was added to 
EAC4 before or after treatment of EAC4 with KBr extract from Raji 
cells. In one case Cl was added to EAC4 and EAC14 were centrifuged 
prior to addition of KBr extract from Raji cells for 1 hour. In the 
other case, pretreatment of EAC4 with KBr extract for 1 hour with sub­
sequent addition of Cl was also performed. As can be seen in experi­
ment 2 of Table 14, prior addition of C1 to EAC4 before treatment with 
KBr extract from Raji cells virtually eliminated previously observed 
inhibition of subsequent lysis. These results suggested the possibil-
TABLE 14 
INFLUENCE OF KBR EXTRACT FROM RAJ! CELLS ON Cl 
E xperiment 150 
2.23 
2 2.20* 
.29** 
Inhibition (Z') 
Extract u9/ml 
75 
1. 70 
1.95 
• 15 
3B 
1.21 
1.26 
.07 
19 
.39 
.65 
.04 
*EAC4 were incubated with KBr extract from. Raji ce 11 s for 
hour and then incubated with 1.8 Z of Cl. 
**EAC4 were incubated with 1.8 Z of Cl and then incubated with 
KBr extract from Raji cells for 1 hour. 
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ity that KBr extract from Raji cells had an effect on C4b similar to 
that seen on C3b mich affected its function in the classical pathway 
C3 convertase. Tb address the possibility, �14 were treated with 
VBS or KBr extract fran Raji cells at 600 ug/ml. After 1 hour at 37° 
C, both untreated and treated �14 were used to quantitate human C2. 
C2 titers were not altered by pretreatment of �4 with KBr extract 
from Raji cells, changing from 4615 un its/ml (Z) for untreated �14 
to 3750 units/ml (Z) for �14 that had been treated with extract. 
Similar arrounts of KBr extract from Raji cells had been shown to re­
sult in over 90% inhibition of Cl activity. It was concluded from 
these series of experiments that KBr extract from Raji cells had lit­
tle or no effect on the classical pathway except for an effect on Cl. 
Inhibition of Cl activity required the simulta neous presence of both 
Cl and KBr extract. One possible explanation for these results may be 
the presence of the Clq receptor which is present on Raji cells and B 
lymphocytes (Table 1). 
KBr extract from Raji cells had been shown to have no detectable 
influence on C2 decay from EAC142 (Daniel COnrad, personal conrnunica­
tion). KBr extract from tonsil cells was also tested for its influ­
ence on the classical pathway convertase decay in the following exper­
iment (Figure 27) • �142 were prepared which had approximately 2 
sites of C2 per cell. They were a llowed to decay in the presence of 
VBS in 0.01 M EIYI2\/GVB or 604 ug/ml of KBr extract from tonsil cells 
in 0.01 M ED'm/GVB. After varying times at 30°C, rat senun was added 
as described in the Materials and Methods to detect lysis. The half­
life of the convertase in VBS was·S.S minutes; in KBr extract it de-
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Figure 27. Influence of KBr extract from tonsil cells on decay of 
classical pathway C3 convertase. EAC142 were prepared with approx­
imately 2 z of C2/cell (95% lysis) • EAC142 were then incubated in 
VBS with 0.01 M ED'ffi/GVB or KBr extract (604 ug/ml) in 0.01 M EDTA/ 
GVB for varying time periods at 30°C. 
o-----o VBS. -------- KBr extract fran tonsil cells. 
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clined to 7.8 minutes. This is in oontrast to the reduction of the 
alternative pathway convertase half-life (Table 9) by 57% with only 5% 
of the anount of extract used for the classical pathway convertase. 
Although gp205 has been shown to cause decay of the classical pathway 
convertase as well as the alternative pathway convertase, this experi­
ment suggests that it is much less efficient in the classical pathway. 
Influence of KBr Extract fran Raji and 'lbnsil Cells on Rosette 
Formation with EAC43 
Since the ability to inhibit formation of complement rosettes was 
the original measure of C3b receptor function, KBr extracts fran both 
Raji and tonsil cells were tested for their ability to inhibit ro­
settes between Raji cells and EAC43 bearing both C3b and C3bi (Figure 
28). Both KBr extracts were found to inhibit rosette formation in a 
dose dependent manner. Surprisingly, ability of both KBr extracts to 
inhibit rosettes between Raji cells and EAC43 bearing both C3b and 
C3bi was unaffected by heat treatment whereas their effects in inhibi­
tion of alternative pathway lysis was abrogated by the same treatment 
(Figures 5 and 6). 
Influence of KBr Extracts fran a Number of Raji Cell Lines on Rosette 
Formation 
The various Raji cell lines which had been tested earlier for 
their ability to inhibit the alternative pathway (Table 3) were also 
tested for their capacity to inhibit rosette formation. It is clear 
that although there are substantial differences in inhibition of al­
ternative pathway lysis (Table 3), all cell lines clearly inhibit for­
mation of rosettes as shown in Table 15. 
Figure 28. Inhibition of rosettes by KBr extracts from Raji or 
tonsil cells. KBr extract from Raji cells was preincubated at 0°C 
or at 56°C prior to addition to EAC43. KBr extract from tonsil 
cells was preincubated at 0°C or at 60°C prior to addition to 
EAC43. Both were tested in separate experiments for inhibition of 
rosettes as described in Materials.and Methods. Controls with VBS 
alone were 41 and 43% rosette positive, respectively. 0 KBr 
extract from Raji or tonsil oells preincubated at 0°C. [S3 KBr 
extract from Raji cells preiocubated at 56°C. [s:sl KBr extract 
from tonsil cells preincubated at 60°C. 
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VARIABILI'IY IN RAJ! CELL LINES FOR 
Cell Line 
Raji CN old 
Raji CN new 
Raji ATCX: 
Raji Kumar 
Raji MS 
Raji OC old 
Raji OC new 
INHIBITION OF OOSEITES 
% Inhibition of Rosettes 
62.3 
25.3 
70.7 
47.5 
28.3 
56.5 
21.0 
Inhibition of rosettes was performed in one experiment under 
conditions described in Materials and Methods. All values 
are adjusted for an extract concentration of 1 mgjml. 
Percent rosettes with buffer alone were 43% positive. 
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Relationship of Inhibition of Rosettes due to KBr Extract fran Raji 
and Tbnsil Cells with gp205 
Since anti-gp205 has been shown to inhibit C3b-dependent rosette 
formation on a number of cell types (67), its influence on inhibition 
of rosettes due to KBr extracts fran both Raji and tonsil cells was of 
interest. Because gp205 is internalized by PMNs when it is cross­
linked by antibody, KBr extract from both Raji and tonsil cells were 
preincubated alone or with affinity purified anti-gp205 (Fab')2 on ice 
for 30 minutes and subsequently centrifuged at 48,000 x G for 1 hour. 
This step was included to prevent possible endocytosis of C3b receptor 
by excess anti-gp205. After resuspension of pelleted membrane mater­
ial in VBS, the residual ability of these extracts to inhibit C3b and 
C3bi rosette formation with Raji cells was then tested. Figure 29 il­
lustrates the results of this experiment. Preincubation with 156 ng 
of anti-gp205 removed 65% of the inhibition of rosettes due to KBr ex­
tract from tonsil cells, whereas it had no effect on the ability of 
KBr extract fran Raji cells to inhibit rosettes. The failure of anti­
gp205 to remove inhibition of C3b and C3bi rosette formation due to 
KBr extract fran Raji cells suggests that membranes of Raji cells con­
tain a component antigenically distinct from gp205 but which inhibits 
formation of rosettes. Earlier experiments had suggested that inhibi­
tion of alternative pathway lysis and accelerated decay of EAC43bBb by 
KBr extract from Raji cells were also not due solely to gp205 (Figure 
20, Table 13). Inhibition of C3b and C3bi dependent rosette formation 
due to KBr extract from tonsil cells is however due in part at least 
to gp205 since pretreatment of KBr extract with anti-gp205 resulted in 
Figure 29. Inhibition of rosettes by KBr extracts from Raji or 
tonsil cells. KBr extracts from Raji or tonsil cells were prein­
cubated alone or with 156 ng/ml of anti-gp205 (Fab'J2• Con­
centrations of extract used are given in ug/ml. After centri­
fugation and resuspension in VBS, all four were tested for inhi­
bition of rosettes as described in Materials and Methods. Con-
trols of_VBS alone were 45% rosette positive. c=J KBr extract 
from Raji or tonsil cells alone. 
tonsil cells with anti-gp205. 
� KBr extract from Raji or 
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a reduction of inh ibition of 70%. Earlier experiments had shown that 
inhibition of alternative pathway lysis by KBr extract from tonsil 
cells was completely removed by anti-gp205 and that accelerated decay 
of �43bBb was also reduced by anti-gp205 (Figure 20, Table 13). 
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DISC!JSSION 
'lhese studies have examined the capacity of KBr extracts from a 
number of cell types to inhibit alternative pathway lysis of 
�43bBb. TWo separate sources of Raji cells were positive, whereas 
three other sources of Raji cells were negative for inhibition. As 
illustrated in Table 2, upon serial passage, both cell lines which 
inhibited alternativ.e pathway lysis were subsequently negative. The 
reasons for this change are not clear. '!he possibility that the ob­
served variability among various Raji cell lines is due to differ-
ences in cell cycle seems unlikely for several reasons. First, all 
spinner flasks were established with cell concentrations of 1 x 105 
per ml and cultured till the cell number was sanewhere between 1 x 
109 to 2 x 109 per ml depending on the cell type. Secondly, both 
positive and negative extracts were prepared concurrently from two 
different cell lines cultured in separate spinner flasks which were 
begun at identical densities, terminated on the same day, and con-
tained equivalent numbers of cells. Lastly, the ability to inhibit 
alternative pathway lysis was consistently found in the two positive 
cell lines for long periods of time in over 15 individual membrane 
preparations. 
Previous experiments (Figure 12) had shown that 1 mM FMSF had no 
effect on the ability of KBr extracts from Raji and tonsil cells to 
inhibit alternative pathway lysis. Because of the failure to extract 
active material from three Raji cell lines, an extract from one nega-
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tive cell line was prepared in the presence of 1 roM PMSF throughout 
the entire procedure of cell disruption, membrane ioolation, and 
extraction (Figure 13). The extract prepared in this manner still 
failed to inhibit alternative pathway lysis. 
other workers have observed variable expression of C3b recep­
tors. The expression of the C3b rec:ptor on FMNs depends on the dif­
ferentiation state of the cell (89). Also, the C3b receptor on B 
lymphocytes is lost as the cell matures to a plasma cell (90). Re­
cently, Ryan, Schultz and Ryan have reported that both Fe and C3b 
receptors are induced in bovine pulmonary endothelial cells by leu­
kocyte lysates or infection with cytomegalovirus or influenza virus 
(91) • Together, these reports suggest that a variety of cell types 
are influenced both by differentiation state and influences of viral 
infection or inflammatory stimuli on expression of the C3b receptor. 
Since the Raji cell line has been in culture in many laboratories 
since 1965, it is not surprising that variability for a number of 
characteristics reported for these cells should occur. In addition, 
the serendipitous observation of an inhibitor(s) in both calf and hu­
man serum of inhibition of alternative pathway lysis due to KBr ex­
tract fran Raji cells (Figures 17 and 19) demonstrates external in­
fluences on the function and perhaps even the expression of the mem­
brane component responsible for inhibition. 
Inhibition of alternative pathway lysis by KBr extracts from 
Raji cells was dependent on both time and temperature of pretreatment 
of �43 (Figure 7, Table 2). These results provide evidence against 
the possibility that the observed inhibition of lysis was due to an 
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effect of extract on CS-c9, which oonstitute the terminal corrplement 
oomponents responsible for hemolysis. Although definitive studies 
utilizing limiting ooncentratians of each of the terminal components 
were not done, the dependence on time and temperature of pretreatment 
of EAC43 for inhibition by KBr extract from Raji cells supports a di­
rect effect on C3b itself. 
Since the C3b receptor an both human erythrocytes and PMNs is 
trypsin sensitive (28, 29), KBr extract from Raji cells was treated 
with trypsin, pronase or protease. These proteolytic treatments of 
KBr extract from Raji cells were unsuccesful in eliminating inhibi­
tion of alternative pathway lysis (Figures 14 and 15). The failure 
of all of these enzymes to eliminate inhibition of lysis suggests two 
possibilities. The more obvious oonclusion is that inhibition of al­
ternative pathway lysis is not due to a protein or glyooprotein which 
is susceptible to cleavage by these enzymes. Alternatively, the rel­
ative insolubility of KBr extracts which have been dialyzed against 
VBS may limit access of the enzymes to the extract, particularly with 
enzymes oovalently bound to Sepharose. 
KBr extracts from membranes of isolated mononuclear cells in 
tonsils also inhibited alternative pathway lysis (Figure 5). This 
result was expected since tonsils oontain a substantial percentage of 
B lymphocytes and macrophages, previously shown by Fearon to possess 
gp205 (67). Inhibition of alternative pathway lysis was similar to 
that. seen with KBr extracts from Raji cells. Inhibition by both was 
dependent on ooncentration of extract and was lost when extract was 
heated· to 56 or 60 C before use. In addition, inhibition of alter-
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native pathway lysis by KBr extract from tonsil cells was also sen­
sitive to calf serum (Figure 18). However, unlike the variation seen 
with Raji cell lines, every preparation of KBr extract from tonsil 
cells inhibited alternative pathway lysis. 
The relationship of alternative pathway inhibition by KBr ex­
tracts to gp205 was a central question in these studies. Two inde­
pendent sources of anti-gp205, a heteroantiserum and a monoclonal 
antibody were used. (Fab'l2 anti�205 from Dr. Douglas Fearon re­
moved all inhibition of alternative pathway lysis by KBr extract from 
tonsil cells, while 50% of inhibition by KBr extract from Raji cells 
was retained (Figure 20) . Similar results were obtained using a 
monoclonal antibody from Drs. Gerdes and Stein (Figure 21) . '!bus, 
inhibition of alternative pathway lysis by KBr extract from Raji 
cells, though similar to gp205 in other respects, was due at least in 
part to a component antigenically distinct from gp205. 
Another important question was the possible relationship of in­
hibition of alternative pa�,way lysis by KBr extracts to either fac­
tor H or I. '!his was particularly relevant since Lambr is et al ( 41) 
have reported the presence of endogenous factor I from both Raji 
cells and normal B lymphocytes. Adsorptions of KBr extracts from 
both Raji and tonsil cells by antibodies to factor H and I conjugated 
to Sepharose failed to remove the oomponent(s) in either extract re­
sponsible for inhibition of alternative pathway lysis (Tables 4 and 
5) . 'Ihese results are consistent with the report by Dobson et al, 
since release of endogenous factor I required the interaction of fac­
tor H with its receptor on the cell. 
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The functional similarity of both KBr extracts to factor H was 
also studied. Factor H is essential for cleavage of fluid-phase C3b 
by factor I (21). Fearon also showed that gp205 functions in a simi­
lar manner with factor I. In agreement with Fearon, KBr extract fran 
tonsil cells served as a cofactor for factor I on cleavage of fluid­
phase C3b (Figure 26). However, KBr extract fran Raji cells failed 
to serve as a cofactor for C3b cleavage (Figure 25). Since about 50% 
of inhibition of alternative pathway lysis by KBr extract fran Raji 
cells was removed by anti-gp205, the failure of this extract to serve 
as a cofactor for factor I was sanewhat surprising although the con­
centration of gp205 in the KBr extract from Raji cells may have been 
too low. In any case, the inability of KBr extract fran Raji cells 
to function as a cofactor in cleavage of fluid-phase C3b provides ad­
ditional evidence against endogenous factor H as the component in ex­
tract responsible for inhibition of alternative pathway lysis, as 
well as showing that the additional components which are not inhibit­
ed by gp205 do not provide cofactor activity. 
The role of factor H in regulation of the alternative pathway 
was originally detected through its synergy with factor I on cell­
bound C3b. KBr extract fran Raji cells was tested for its ability to 
synergize with factor I on cell-bound C3b. Addition of KBr extract 
to lCM amounts of factor I resulted in ooly an additive increase in 
inhibition of hemolysis (Daniel Oonrad, personal communication) • An 
analogous experiment using KBr extract from tonsil cells in the pres­
ence of lCM concentratioos of factor I on cell-bound C3b was per­
formed (Figure 24). Unlike its effect on fluid-phase C3b in the 
135 
presence.of factor I, KBr extract from tonsil cells resulted in only 
additive inhibition of lysis due to limited cell-bound C3b. The 
ability of KBr extract from tonsil cells (gp205) to serve as a co­
factor for factor I in cleavage of fluid-phase C3b contrasts with its 
fa ilure to serve as a cofactor for inactivation and presumed cleavage 
of cell-bound C3b. This observation has not been previously report­
ed. It may be significant in view of the postulated role for gp205 
in adsorptive endocytosis. It would be of interest to test the abil­
ity of KBr extract from tonsil cells to serve as a cofactor for 
cleavage of C3b on immune complexes, for example. 
KBr extracts from both Raji and tonsil cells were examined for 
their ability to accelerate decay of the alternative pathway C3 con­
vertase, EAC43bBb. Since KBr extract from tonsil cells contained 
gp205, it was expected that it would cause accelerated decay of the 
alternative pathway C3 convertase. Both extracts shortened the half­
life of the convertase (Tables 7 and 8). In the case of KBr extract 
from Raji cells, loss of 125I factor B from the alternative pathway 
convertase on zymosan was also demonstrated. 
Previous work had shown that fluid-phase C3 and C3b inhibited 
birrling of factor H to C3b (88). Therefore, C3, C3b and C3bi were 
tested for their ability to block the accelerated decay of the con­
vertase due to both extracts. Fluid- phase C3 was without effect on 
accelerated decay b¥ either extract. C3 did block accelerated decay 
due to factor H (Table 9), which is consistent with its ability to 
inhibit binding of factor H to cell-bound C3b. Accelerated decay of 
FJIC43bBb b¥ both factor H and KBr extract from tonsil cells was inhi-
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bited by fluid-phase C3b (Table 10) • Interaction of gp205 in KBr 
extract fran tonsil cells with its ligand, C3b, might be expected to 
remove the extract's ability to accelerate decay of �43b8b. In 
contrast to these results, identical amounts of C3b were without 
effect on the shortened half-life of the C3 convertase due to KBr ex­
tract fran Raji cells. These results are consistent with previous 
experiments which implicated another corrponent distinct from gp205 in 
Raji cells in inhibition of alternative pathway lysis. Because Raji 
cells are reported to bear receptors for C3bi, this C3 cleavage prod­
uct was tested for its ability to block accelerated decay of the con­
vertase by KBr extracts (Table 11). Fluid-phase C3bi was without 
effect on shortened half-life induced by either extract, while it in­
hibited accelerated decay due to factor H. The failure of C3bi to 
inhibit accelerated decay by KBr extract from tonsil cells is consis­
tent with the specificity of gp205 for C3b. Its failure to inhibit 
accelerated decay by KBr extract from Raji cells suggests that it is 
oot the C3bi receptor on Raji cells which is involved in decay of the 
C3 convertase. One alternative which was not examined is the final 
cleavage product of C3, which is C3d. In addition to receptors for 
C3bi, Raji cells also have receptors for C3d (44). 
As discussed earlier, treatment of KBr extracts with anti-gp205 
completely removed inhibition of alternative pathway lysis by KBr ex­
tract from tonsil cells while it removed ooly 50% of inhibition by 
KBr extract from Raji cells. Therefore, its effect on accelerated 
decay of �43b8b by both extracts was examined. KBr extract from 
tonsil cells shortened the half-life of the convertase from 8.8 
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minutes to 3.8 minutes. In the presence of 5 ug/ml of (Fab')z 
anti-gp205, KBr extract from tonsil cells did not appreciably alter 
the half-life of the C3 convertase; 0.63 ug/ml of anti-gp205 had an 
intermediate effect resulting in a half-life of 5.8 minutes. These 
results agree with previous reports on the activity of gp205 on decay 
of EI\C3bBb. The same amounts of anti-gp205 did not affect the short­
ened half-life of FAC43bBb by KBr extract from Raji cells in a dose­
dependent manner. B oth shortened half-life of the alternative path­
way C3 convertase ana inhibition of alternative pathway lysis by KBr 
extract fran Raji cells differ from gp205 in similar extracts from 
tonsil cells in their insensitivity to inhibition by anti-gp205 and 
are presumbably due to an antigenically distinct rnolecule(s). 
Although these studies were focused an the alternative pathway, 
several experiments addressed potential effects of KBr extracts on 
the classical pathway. KBr extract from Raji cells was found to have 
a pronounced effect on the activity of Cl when Cl and extract were 
incubated with FAC4 before addition of C2 (Table 14). Since inhibi­
tion required the simultaneous presence of both Cl and extract, the 
trivial explanation for these results is chelation of calcium by mem­
brane fragments. However, these results may also be due to the Clq 
receptor on Raji cells (92). 
Because of the similarity of the classical and alternative C 3  
convertases, the ability o f  KB r  extracts to accelerate decay of 
FAC142 was examined. KBr extract from Raji cells was unable to cause 
accelerated decay of the classical pathway C3 convertase (Daniel 
eairad, personal corrrnunicatian) ·• KBr extract from tonsil cells was 
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tested -for its ability to shorten the half-life of the classical 
pathway convertase (Figure 27). The observed half-life in the pres­
ence of extract did not differ from the control. These results ap­
pear to contradict those of Iiada and Nussenzweig (72) who showed 
that gp205 accelerated decay of EAC142 as well as EAC3bBb. However, 
accelerated decay of the classical pathway convertase requires ap­
proximately ten times_ as much gp205 .as is required for equivalent ac­
celerated decay in the alternative pathway. Thus, the failure to see 
an alteration in half-life of the classical pathway convertase by KBr 
extract from tonsil cells is very likely due to an insufficient con­
centration of gp205. "Alternatively, differences in activity may be 
due to the cell source used. 
Inhibition of complement-dependent rosettes was the original 
functional assay for complement receptors. Dierich and Reisfield 
shooed that· KBr solubilized membrane components from Raji cells inhi­
bited complement-dependent rosettes (62). Figure 28 confirms their 
results using identical extracts from Raji cells. KBr extracts from 
tonsil cells also inhibited complement-dependent rosettes. Previous 
experirilents shCMed that incubation of both extracts at 57 or 60 C for 
30 minutes eliminated their ability to inhibit alternative pathway 
lysis. However, extracts which had been heated retained their abili­
ty to inhibit complement-dependent rosettes. 
TO determine whether inhibition of rosettes by either extract 
was due to gp205, (Fab')2 anti-gp205 was tested for its ability to 
block inhibition of rosettes by both KBr extracts (Figure 29). Anti­
gp205 did remove a substantial amount of inhibition of rosettes by 
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KBr extract from tonsil cells. This result was expected since earli­
er experiments had confirmed the presence of gp205 in these ex­
tracts. Anti-gp205 had no effect on inhibition of complement­
dependent rosettes by KBr extract fran Raji cells. These results 
agree with earlier experiments in which KBr extract from Raji cells 
retained its hemolytic effects in the presence of anti-gp205. 
Several important questions have been raised by the results ob-
tained in these studies. The most obvious question remains the iden-
tity of the component(s) in KBr extract from Raji cells involved in 
inhibition of alternative pathway lysis and accelerated decay of the 
alternative pathway convertase. It is clearly not gp205; the inabil-
ity of C3bi to inhibit its effect on half-life of the convertase sug­
gests that it is not the C3bi receptor. Use of C3d and/or antibody 
to the C3d receptor would be informative about the possible role of 
the C3d receptor on inhibition of alternative pathway activity. 
Another useful series of experiments would include investigation 
of the expression of the coq>onent in Raji cells involved in regula­
tion of the alternative pathway. Negative cell lines might be ex­
posed to a number of factors which have been shown to increase ex­
pression of complement receptors on epithelial cells by Ryan et al 
(91), and on eosinophils by Anwar, Kay and their colleagues (93, 94, 
95, 96). The requirement for substantial numbers of cells for ex­
tract preparation might preclude such studies. The ability to test 
for expression of the component regulating complement activity uti­
lizing 5 x 107 to 1 x 108 cells would be necessary. 
The third area of investigation which these studies suggest is 
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the ability of serum to eliminate effects of both Raji and tonsil 
cells on regulation of alternative pathway lysis. Gp205 is ten times 
as effective per m::>lecule as factor H in serum in causing decay of 
the alternative pathway convertase. (16, 23) Limitation of its 
influence to the cell surface bearing gp205 might be necessary to 
insure plasma complement activation. The presence in serum of a 
factor(s) preventing the fluid-phase function of gp205 would play an 
important role. Further work will be required to address this 
possibility. 
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Appendix I 
A. Stock solutions 
Stock 1 5 X WS 
85 grams NaCl 
3.75 grams Na 5,5' diethyl barbital 
5.75 grams 5,5' diethyl barbituric acid 
pH 7.5 
quantity suff icient (qs) to 2 liters 
Stock 2 Isotonic ED� (0.086 M) 
Dissolve 89.34 gm � in 1 liter of 
distilled water. 
pH 7.5 with 0.3 M Sodium Hydroxide 
qs to 2 liters 
Stock 3 ws 
B. Buff ers 
o5w++ 
200 m1 of Stock 1 
qs to 1 liter 
200 ml of Stock 1 with 0.5 rrM M:]Cl2 and 
0.15 rrM C aCl2 
qs to 1 liter 
2000 ml distilled H20 with 0.5 rrM MgCl2 
and 0.15 m M C aCl2 and 100 gm of de xtrose 
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.01 M ED'm/ 
GVB 
• 04 M ED'm/ 
GVB 
Mannitol/ 
GVB* 
KI reagent 
Alsever's 
solution 
equal volumes of GVB* and 5 % dextrose 
with 0.5 rrM MgCl2 
-and 0.15 mM cac12 
870 m1 Stock 1. 120 m1 Stock 2. 
10 ml of 10% gelatin 
510 ml Stock 1 480 m1 Stock 2 • 
10 ml of 10% gelatin 
30 ml of 25% rnanni tol in dis tilled water 
20 ml of GVB* 
volumes of .1 M Na2HP04 and 
.1M NaH2P04 which give pH 6.0. 
0.25 grn !2 
8.3 grn KI in 100 ml 0.1 M P04 
21.0 grn dextrose 
8.0 grn sodium citrate 
4.2 grn NaCl 
0.4 grn citric acid (anhydrous) 
qs one liter. pH 6-6.5 
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Reagent 
A 
Anti-gp205 
(Fab')2 
Anti-<::3 
Receptor 
Anti-IgE 
Cl 
C2 
C3 
C3b 
C5 
CNBr 
dextrose 
factor B 
factor D 
factor H 
factor I 
FCS 
Ficoll-Hypaque 
G-25 
gelatin 
HEPES 
KBr 
A£:pendix 
Source 
Dr. s. Ruddy 
Dr. D. Fearon 
Dr. H. Stein 
Dr. D. Conrad 
Dr. S. Ruddy 
Dr. S. Ruddy 
Dr. D. Conrad 
Dr. H. Schenkein 
Dr. s. Ruddy 
II 
Sigma Chemical, St. Iouis, MI 
Fisher Scientific, Pittsburgh, PA 
Dr. S. Ruddy 
Dr. S. Ruddy 
Dr. S. Ruddy 
Dr. S. Ruddy 
GIBO), Grand Island, NY 
Bionetics lab ., Kensington, MD 
Pharmacia, P iscataway, NJ 
BBL Microbiol., Cockeysville, MD 
calbiochem, La Jolla, CA 
Fisher Scientific, Pittsburgh, PA 
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lactoperoxidase Calbiochem, La Jolla Ca 
mannitol Dexter Corp., Chagrin Falls, OH 
monoethanolamine Fisher Scientific, Pittsburgh, PA 
nitrocellulose Beckmc:m Scientific, Silver Spring, MD 
tubes 
NaCl Fisher Scientific, Pittsburgh, PA 
Na 125I New England Nuclear, Boston, MA 
NBCS GIBOJ, Grand Island, NY 
NP-40 . Particle Data, Elmhurst, IL 
p ronase Sigma Chemical, St. Louis, MI 
protease Sigma Chemical, St. Louis, MI 
rat serum Pel-Freeze, Rogers, AK 
R3 Dr. S. Ruddy 
R345 Dr. S. Ruddy 
RIM! 1640 GIBOJ, Grand Island, NY 
SD5-PAGE BioRad, Richmond, CA 
reagents 
SBTI 
s-200 
5-300 
Sephacryl Cl-4B 
Suramin sodium 
tissue culture 
reagents 
zymosan 
Sigma Chemical, St. Louis, MI 
Pharmacia, Piscataway, NJ 
Pharmac ia, Piscataway, NJ 
Pharmacia, Piscataway, NJ 
FBA Pharmaceuticals, N.Y., NY 
Bell=, Vineland, NJ 
Sigma Chemical, St. Louis, MI 
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Model 250 Spectrophotometer Gilford Instruments 
Automatic Garrrna Amersham-Searle Corp. 
Scintillation Counter 
C02 Incubator Forma Scientific 
Series 2200 Computer Wang Laboratories 
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Oberlin, OH 
Des Plains ; IL 
Marietta, OH 
Tewksbury, MA 
